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Healthcare is a field where the early detection of diseases is becoming more and 
more important. Nowadays, professionals and citizens demand high quality diagnosis 
techniques offered by both private and public health systems. When the application of 
diagnostic tests is not adequate, different consequences can be observed such as health 
hazard and technical and economic overload of health services. This is due to the fact that 
the diagnostic techniques available are expensive, centralized in laboratories and with the 
need for highly qualified professionals to carry out these tasks, what can fundamentally 
lead to delays in time, being critical for the patient's health. It is very necessary, therefore, 
to reflect on the need and emergency of such preventive practices, especially for high-
risk diseases such as cancer, Alzheimer or the first cause of death in the world, the 
cardiovascular diseases. 
Within this context, the main objective of the work done during this PhD Thesis is to help 
on overcoming these problems by exploring the possibility of using photonic technology 
for the development of analysis devices which might be used for the early diagnosis and 
prognosis of cardiovascular diseases. This objective has been addressed by combining 
nanophotonic technology, by the nanofabrication of the photonic PBG sensing structures, 
which provides several benefits such as a high sensitivity, an extreme size reduction and 
a fabrication process being compatible with that from the microelectronics industry, with 
a light-assisted biofunctionalization method forming a stable and selective biorecognition 








El cuidado de la salud es un campo en el que la detección precoz de enfermedades 
está cobrando cada vez más importancia. Hoy en día, profesionales y ciudadanos 
demandan que las técnicas de diagnóstico sean de alta calidad, tanto para el sistema de 
sanidad privado como para el público. Cuando se utilizan técnicas de diagnóstico de 
manera inadecuada, eso puede acarrear bastantes consecuencias, tales como un serio 
peligro sobre la salud y la sobrecarga técnica y económica de los servicios de salud. Eso 
es debido a que las técnicas de diagnóstico disponibles hoy en día son demasiado costosas, 
centralizadas en laboratorios y necesitan profesionales altamente cualificados para poder 
llevar a cabo dichas tareas, lo que conllevaría una demora en el tiempo, siendo este 
muchas veces vital para los enfermos. Es muy necesario, por lo tanto, reflexionar sobre 
la necesidad y emergencia de tales prácticas preventivas, especialmente para 
enfermedades de alto riesgo como el cáncer, el Alzheimer o la primera causa de muerte 
en el mundo, las enfermedades cardiovasculares.  
En este contexto, el objetivo principal del trabajo realizado durante esta Tesis Doctoral 
es ayudar a superar estos problemas mediante la exploración de la posibilidad de utilizar 
tecnología fotónica para el desarrollo de sistemas de análisis que puedan ser utilizados 
para el diagnóstico y pronóstico de las enfermedades cardiovasculares. Este objetivo se 
ha abordado mediante la combinación de la tecnología nanofotónica, consistiendo en la 
nanofabricación de las estructuras PBG de sensado que ofrece varios beneficios, como 
una alta sensibilidad, una extrema reducción de tamaño y un proceso de fabricación 
compatible con el de la industria microelectrónica, con un método de biofuncionalización 
obteniendo una capa de bioreconocimiento estable y selectiva mediante el uso de la 
reacción TEC asistida por luz capaz de proporcionar unas capas de bio-reconocimiento 





  Resum 
 
L'atenció a la salut és un camp en què la detecció precoç de malalties està cobrant 
cada vegada més importància. Hui en dia, professionals i ciutadans demanen que les 
tècniques de diagnòstic siguin d'alta qualitat, tant per al sistema de sanitat privat com per 
al públic. Quan s'utilitzen tècniques de diagnòstic de manera inadequada, això pot 
comportar bastants conseqüències, com ara, un seriós perill sobre la salut i la sobrecàrrega 
tècnica i econòmica dels serveis de salut. Això és degut al fet que les tècniques de 
diagnòstic disponibles hui en dia són molt costoses, centralitzades en laboratoris i 
necessiten professionals altament qualificats per poder realitzar aquestes tasques, lo que 
comportaria a una demora en el temps que moltes vegades es vital pels malalts. És molt 
necessari, per tant, reflexionar sobre la necessitat i emergència de tals pràctiques 
preventives, especialment per a malalties d'alt risc com el càncer, l'Alzheimer o la primera 
causa de mort al món, les malalties cardiovasculars. 
En aquest context, l'objectiu principal del treball realitzat durant aquesta Tesi 
Doctoral és ajudar a superar aquests problemes mitjançant l'exploració de la possibilitat 
d'utilitzar tecnologia fotònica per al desenvolupament de sistemes d'anàlisis que puguin 
ser utilitzats per al diagnòstic i pronòstic de les malalties cardiovasculars. Aquest objectiu 
s'ha abordat mitjançant la combinació de la tecnologia nanofotònica, consistint en la 
nanofabricació de les estructures de detecció de PBG fotòniques que ofereix diversos 
beneficis, com una alta sensibilitat, una extrema reducció de mida i un procés de 
fabricació compatible amb el de la indústria microelectrònica, amb un mètode de 
biofuncionalització obtenint una capa de bio-reconeixement estable i selectiva mitjançant 
l'ús de la reacció TEC assistida per llum capaç de proporcionar unes capes de bio-




































ADC: analog-to-digital converter. 
AFM: Atomic Force Microscope. 
AntiBSA: BSA antibody. 
APTES: (3-Aminopropyl)triethoxysilane. 
BSA: Bovine Serum Albumin. 
CCD Camera: Charged Coupled Device Camera. 
CRP: C-Reactive Protein. 
cTn: Cardiac Troponin. 
cTnC: cardiac Troponin Calcium. 
cTnI: cardiac Troponin Inhibitor. 
cTnT: cardiac Troponin Tropomyosin. 
CVD: Cardiovascular diseases. 
DNA: Deoxyribonucleic acid. 
DIW: Deionized Water. 





EBL: Electron Beam Lithography. 
EDTA: Ethylenediaminetetraacetic acid. 
EHN: European Heart Network. 
ELISA: Enzyme-Linked ImmunoSorbent Assay. 
EtOH: Ethanol. 
FDTD: Finite-difference time-domain method. 
Gln: Glutamine. 
Glu: Glutamic acid. 
H2O2: Hydrogen peroxide. 
H2SO4: Sulfuric acid. 
H-Bonds: Hydrogen bonds. 
hIgG: Half immunoglobulin G. 
HSQ: Hydrogen Silsesquioxane. 
IgG: Immunoglobulin G. 
IR: Infrared. 
IRRAS: Infrared Resonance Absorbance Spectroscopy. 
KCl: Potassium chloride. 
KOH: Potassium hydroxide. 
Leu: Leucine. 
LOC: Lab On a Chip. 
LOD: Limit Of Detection. 
Lys: Lysine. 
Mb: Myoglobin. 
MPB: MIT Photonic Bands. 
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NaCl: Sodium chloride. 
NaOH: Sodium hydroxide. 
PBG: Photonic Bandgap. 
PBS: Phosphate-Buffered Saline. 
PBS-T: Phosphate-Buffered Saline-Tween20. 
PCR: Polymerase Chain Reaction. 
PDB: Protein Data Bank. 
PDMS: Polydimethylsiloxane. 
PMMA: polymethyl methacrylate. 
POCT: Point Of Care Testing. 
RCSB: Research Collaboratory for Structural Bioinformatics. 
RI: Refraction Index. 
S: Sensitivity. 
SEM: Scanning Electron Microscope. 
Si: Silicon. 
SiO2: Silicon dioxide. 
SNOM: Scanning Near-field Optical Microscope. 
SOI: Silicon On Insulator. 
SU-8: Sukhoy-8. 
TCEP: tris(2-Carboxyethyl)phosphine. 
TEC: Thiol-ene Chemistry. 
TEVS: Triethoxy-vinyl sialne. 
UV: Ultraviolet. 
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Nowadays, point of care testing (POCT) market is perceiving an even increasing 
demand for novel, effective and cheap devices for diseases early 
diagnosis/detection. Among these diseases, there is an even special interest for 
cardiovascular diseases (CVD) which is the leading cause of death worldwide with 
17.9 million deaths. The recent statistical report of 2017 of the European Heart 
Network (EHN) depicts that CVD are the leading cause of death in Europe with 3.9 
million death per year (40% in the European Union). Data according to the 
European Heart Network (EHN, 2017) are shown in figure 1.1, with an estimated 
cost of about 210 € Billion per year. A total amount of 111 € Billions is related with 
healthcare costs, especially diagnosis and drug therapies, while the rest is for non-
healthcare dispenses. Despite these numbers, CVD can be successfully treated once 
detected correctly and prematurely. From here, the high interest of the 
implementation of effective detection tools, since they are extremely interesting for 




Figure 1.1. Worldwide deaths annual number by causes. Source: European 
Heart Network organization report (2017). 
In cardiovascular diseases, heart failure is the end stage (Pagidipati and Gaziano, 
2013). That heart failure is commonly produced by a damage of the heart 
myofilaments that can lead to systolic failure, resulting on a decrease of the blood 
circulation, not sufficing organism needs (Lee Goldman et al., n.d.). Specifically, 
we can establish that in the correct operation of the cardiovascular system, 
influences not only blood and heart but also the corresponding blood vessels and 
the lymphatic system. This is the last step for the correct working of the transport 
system, both for the regulation of liquids and for defenses and fatty acids. In the 
case of blood vessels, they are classified into elastic arteries, arterioles, muscle 
arteries, capillaries and veins (Hurst et al., 1974). 
 
Types of cardiovascular diseases: 
• Coronary heart disease (CHD) is the most common type of heart disease and 
occurs when plaque builds up in the arteries that lead to the heart. It is also 
called coronary artery disease (CAD). When the arteries narrow, the heart 
cannot receive enough blood and oxygen and can cause a heart attack. Over 
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time, CHD can weaken the myocardium and cause heart failure or 
arrhythmias. 
• Heart failure occurs when the myocardium becomes stiff or weak and it 
cannot pump enough oxygenated blood, which causes symptoms 
throughout the body. The disease can affect only the right side or the left 
side of the heart. Nevertheless, it is very common that both sides of the heart 
are compromised. High blood pressure and CAD are common causes of 
heart failure. 
• Arrhythmias are problems with heart rate (pulse). This happens when the 
electrical system of the heart does not work properly, making it to beat too 
fast, too slow or irregularly. Some heart problems, such as a heart attack or 
heart failure, can cause problems with electrical system of the heart. Some 
people are born with an arrhythmia.  
• A stroke is caused by a lack of blood flow to the brain. This can happen due 
to a blood clot that travels to the blood vessels in the brain or a bleeding in 
the brain. Stroke has many of the same risk factors as heart disease. 
• Congenital heart disease is a problem with the structure and functioning of 
the heart that is present at birth. This term can describe many different 
problems that affect the heart. It is the most common type of congenital 
anomaly. 
As for almost all diseases, an early detection of CVD is crucial for an efficient 
treatment and prognosis. Thus, the development of an effective, sensitive and 
reliable detection tool is of a high importance. In this sense, biosensors should meet 
all of the requirement needed for such detection devices. 
A biosensor is an analytical device used in the detection of chemical and/or 
biological substances, which combines chemical and biological components with a 
transducer. The different components of a biosensor are: 
• Recognition layer: Known as the surface or interface of interaction 
between the receptor and the target analyte/molecule. Chemical receptors, 
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nucleic acids, aptamers, enzymes and antibodies are some examples of these 
recognition elements. 
• Transducer: It is the element responsible for converting the biorecognition 
event taking place in the recognition layer into a reliable and measurable 
output physical signal. Electrochemical, optical and mechanical transducers 
are some examples of transducer. 
• Signal processor: It is in charge of acquiring and processing the signal from 
the transducer. 
Among other parameters, sensitivity, selectivity, response time and limit of 
detection are the characteristic parameters to evaluate the biosensing device 
performance: 
• Sensitivity: is the relationship between the variation of the sensor output 
signal as a response to a physical quantity variation and the physical 
quantity variation itself. In general, sensitivity is the slope of the calibration 
curve. This parameter defines the ability of the sensor to detect that variation 
and to transduce it into a measurable signal. 
• Selectivity: refers to the capability of the sensor to detect the specific target 
analyte with no interference with other non-targeted elements so called 
interferents. 
• Response time: is the needed time by a sensor to perceive the variation of 
a physical quantity and to react to it. This requirement may be crucial for 
those applications where a prompt response is needed.  
• Limit of detection (LOD): is defined as the minimum amount of analyte 
concentration that can be detected by the sensor. For optical sensors, this 
parameter is calculated considering the ratio between the noise of the 
measurement and the sensitivity of the sensor. 
During the recent last years, we have witnessed a great interest in the development 
of high-performance lab-on-a-chip (LOC) biosensing devices that are able to 
replace conventional methodologies currently used, such as PCR or ELISA, which 
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are expensive, bulky, time-consuming and lab-centralized (Chin et al., 2007; Wu et 
al., 2017). The combination of microfluidics and nanoscale transduction elements 
based on different mechanisms, such as optical, electrical, or mechanical (Estevez 
et al., 2012; Johnson and Mutharasan, 2012; Vestergaard et al., 2007), allows to 
perform the required analyses with high sensitivity, a high degree of 
miniaturization, a high multiplexing level, shorter time to results and requiring very 
low volumes of sample. 
From these biosensors, optical/photonic sensors have gained much interest, due to 
their extremely high sensitivity, fast response and reduced size, which permits to 
integrate several sensing structures on a single chip for an ultra-sensitive 
multiplexed detection. These characteristics make photonic sensors highly 
attractive for several application areas, such as chemical, biological, defense, 
industry and biomedical fields. Furthermore, such devices allow the development 
of label-free assays where the use of radioactive, colorimetric or fluorescent labels, 
which introduce complexity and loss of activity to biological molecules are avoided 
(Fernández Gavela et al., 2016; Hunt and Armani, 2010; Zanchetta et al., 2017). 
Therefore, reduced size advanced label-free biosensors can provide selective, 
sensitive, fast and direct detection of a certain target analyte at extremely low 
concentrations.  
The healthcare crews, the EU governments and the scientific communities, have 
approved the implementation of nanotechnology sensing tools for the current and 
future market, as they show improved features and functionalities compared to the 
conventional ones. Within those nanotechnology tools, nanophotonics is emerging 
as one of the highly effective transducers due to the several advantages that it 
provides, as for example, high sensitivity, reproducibility, label-free detection, 
compactness, high integration level and low-cost mass production.  
The overall objective of this PhD thesis has been working in the development of an 
integrated photonic biosensing system suitable for its use in a LOC device in a near 
future. More specifically, the work carried out has aimed at making a proof of 
concept of the capability of detecting the selected CVD biomarkers at the required 
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concentration using a biosensor combining nanofabricated photonic sensors and a 
light-assisted biofunctionalization protocol for the immobilization of specific 
bioreceptors to those biomarkers. 
 
1.2. CVD biomarkers 
The National Institute of Health Consortium in 2001 defined a biomarker as a 
“characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to 
a therapeutic intervention” (Arthur J. Atkinson, 2001). Subsequently, in 2009 the 
American Heart Association outlined the extensive criteria for how newer 
biomarkers should be evaluated in a standardized fashion before their clinical use 
can be recommended (Hlatky et al., 2009). More generally, the characteristics of an 
ideal biomarker to be used for a given purpose in any disease condition, with a 
special emphasis on CVD, are detailed in some reviews (Hlatky et al., 2009; Wang, 
2011). 
Biomarkers play an important role in the evaluation and detection of diseases as 
well as in the development of targeted drug treatments for those disease conditions. 
In the late phases of drug development, biomarkers can even be helpful in 
determining the accurate dose for any given drug. In more recent times, biomarkers 
are being considered as surrogate endpoints for clinical trials as well. More recently, 
there has been a shift towards the development of precision medicine, especially 
with a focus on development of drugs and highly sensitive sensing devices. 
Furthermore, in hospitals, many patients who present a suspected heart disease have 
a final diagnosis which excludes an acute coronary event and do not have 
underlying cardiovascular disease. Here, 5-7% of patients are turned back home 
from hospital inappropriately due to this mistaken diagnosis. Hence, an adequate 
POCT device will enable a fast and accurate diagnosis in an earliest stage, allowing 
the repetition and analysis of several biomarkers in the same time to ratify the 
results in a very short time, low cost, in-situ and using only few drops of finger’s 
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blood. Furthermore, POCT used in healthcare systems will represent a decrease of 
25% from the previously mentioned costs of healthcare service, which represent an 
amount of 3700 € per patient, which means 29 € billion of save in total European 
healthcare system. 
Within this context, several CVD biomarkers have been widely studied. In this 
work, proteins such as C-Reactive Protein (CRP), cardiac troponin (cTn) subunits 
and Myoglobin (Mb) were considered due to their accuracy, precision, high 
sensitivity and specificity, which make them ideal CVD biomarkers (Arthur J. 
Atkinson, 2001). 
Some of those biomarkers are not highly specific for cardiovascular diseases but 
very important indicators (as for example, CRP). Among all the previously 
mentioned biomarkers Myoglobin, cTnI and cTnT were highly considered for our 
sensing tool. Note that the biomarkers levels increase notably when a heart attack 
of the myocardium happens, showing different values depending on the time after 
a cardiovascular episode. The CVD biomarkers levels evolution versus time are 
depicted in figure 1.2.  
 
Figure 1.2. Release timing of biochemical markers following acute myocardial 
infarction in units of release. Adapted from Clin Chem. 1999;45(7):1104-1121. 
11 
 
Furthermore, the development of a sensing device capable to measure in real-time 
several biomarkers at the same time is of high interest, since the multiplexed 
systems are more accurate. 
 
C-Reactive Protein (CRP) 
CRP is a pentagonal protein (see figure 1.3) with about 126 kDa molecular weight, 
which is considered as a general marker for inflammation and infection. Therefore, 
it can be used to determine the risk of suffering an acute myocardial infarction.  
Considered as a member of the acute phase reagents class or acute phase protein, 
CRP levels increase dramatically during the bodily inflammatory processes. From 
here, high CRP levels can have multiple causes related with inflammatory 
processes, so it is not a very specific test for CVD diagnosis. However, the finding 
of a CRP concentration higher than 2.4 μg/mL doubles the risk of suffering a 
coronary event respect having concentrations lower than 1 μg/mL; so, despite not 
being very specific, it can guide the diagnosis and help on establishing the risk (St-
Onge et al., 2009). Normal CRP values, which might vary from one laboratory to 
another, are typically in the range of 0.25 μg/mL to 3 μg/mL. 
 






Myoglobin is a muscular hemoprotein, functionally and structurally like 
hemoglobin, whose function is the storage of oxygen (Collman et al., 1976). With 
a molecular weight of only 17.2 kDa, myoglobin is a small protein constituted by a 
polypeptide chain of 153 amino acid residues and by a ``heme´´ group that contains 
an Iron ion (Fe (II)) (see figure 1.4). The heme group is found within a hydrophobic 
cavity of the protein. This non-polypeptide unit is bound (non-covalently) to 
myoglobin and is essential for the biological activity of O2 binding of the protein 
(Ordway and Garry, 2004; Zaia et al., 1992). Myoglobin is released from damaged 
muscle tissue, which has very high concentrations of myoglobin. Normal 
myoglobin range is between 25 to 72 ng/mL and concentrations above 85 ng/mL 
are considered abnormal (again, these are guide values, since they can slightly 
change from one lab to another). As CRP, Myoglobin is a potential marker for 
cardiac injuries, but taking into account that its levels can be varied by other factors 
such as inflammatory and degenerative muscle diseases (Lewandrowski et al., 
2002). 
 
Figure 1.4. Human myoglobin protein. Image source RCSB (PDB code 3RGK). 
 
Cardiac troponin (cTn) 
With a molecular mass of approximately 63 kDa, cardiac troponin is a complex 
composed of three protein subunits (see figure 1.5), having a different role in the 
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myocardial contraction (Gomes et al., 2002). Cardiac troponin T (cTnT) is a 
tropomyosin-binding subunit that regulates the interaction of the troponin complex 
with the thin filaments of the cardiac muscle. Cardiac troponin I (cTnI) inhibits the 
interaction between myosin and actin, responsible of muscle contraction. And 
finally, cardiac troponin C (cTnC) is a Ca2+ binding subunit responsible of 
regulating the muscle contraction depending on the Ca2+ concentration. The binding 
of Ca2+ to cTnC produces a conformational change that reduces the inhibition of 
cTnI and thus leads to muscle contraction. That conformational change produced 
by cTnC is reversed when Ca2+ levels are restored, thus creating the contraction-
relaxation cycle (Alves et al., 2014; Willott et al., 2010). 
When damage of the myofilaments of the cardiac muscle is produced, a break of 
the troponin complex takes place, leading to the release of the troponin subunits 
(cTnT, cTnI and cTnC) to the blood stream. Thereby, the levels of these cardiac 
troponin subunits in blood increases and so can be used as a marker of myocardial 
damage, especially cTnI (Bagai et al., 2015). Concentrations of cTnI subunit over 
10 ng/mL specifically indicates CVD clinical sign. Note that with Mb and CRP, 
cTnI and cTnT are the most specific biomarkers for CVD diseases, from here the 
high interest to develop a LOC device of high sensitivity for this biomarker. 
 
Figure 1.5. Human core cardiac troponin complex in the calcium saturated form. 
Blue = Troponin C, Green = Troponin I, Pink = Troponin T. Image source 
RCSB (PDB code 4Y9.9 
 
Within the field of CVD biomarkers detection, several sensing methodologies have 





colorimetric methods for cardiac marker detection. Here, luminescent signal is 
generated by the action of an enzymatic labelled antibody in the presence of a 
luminogenic substrate, while in the case of electroluminescence, the luminescent 
signal is induced due to an electron transfer reaction of the luminescent bioreceptor 
immobilized near the proximity of an electrode surface (Cai et al., 2018). This 
methodology was successfully demonstrated for CRP detection. From here, 
electroluminescence methods are currently less extensively considered by 
researchers for CVD markers detection at the expense of nanocompounds sensing 
methods (Bakirhan et al., 2018). Based on the ECL of CdS nanocrystals, a novel 
label-free ECL biosensor for the detection of low-density lipoprotein (LDL) as 
CVD biomarker has been developed by using self-assembly and gold nanoparticle 
amplification techniques. Unfortunately, no multiplexed detection versatility in this 
case was offered. Finally, the electrochemical sensing methods. Typically, 
electrochemical biosensors use an electrode transducer to detect the signal 
generated following specific binding or catalytic reactions of surface modifier 
biomaterials such as aptamers, enzymes, antibodies or nucleic acids on the surface 
of a metal or carbon electrode (Zhu et al., 2015). Note that electrochemical 
techniques attracted considerable attention because of special features such as 
simplicity, sensitivity and enable the performance of rapid analysis, but they have 
the drawback of being lab centralized and sometimes expensive. Whereby, the need 
of a new sensing method capable to detect several biomarkers in parallel in a short 
time, cheap and integrable in a POCT device. 
 
1.3. Evanescent wave photonic biosensors   
Within optical biosensors, those based on evanescent wave photonics are emerging 
to be the most prominent and interesting ones, due to their high versatility, 
sensitivity, real-time and label-free detection, thus attracting high interest to 
become real POCT devices in the near future. 
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The detection principle in this type of photonic biosensors consists in the 
quantification of the variation in the effective refraction index that occurs when an 
alteration of the chemical or physical parameters is produced on the surface of the 
structure. This variation is due to the interaction of the optical wave with the 
medium surrounding the sensor surface. When an optical wave is traveling through 
the core of an optical waveguide, a fraction of its energy propagates to the 
surrounding medium, which is known as evanescent wave. This evanescent wave 
is highly intense in the sensor surface and decreases its intensity exponentially when 
z increases as depicted in figure 1.6.  
 
Figure 1.6. Schematic representation of the working principle of an evanescent 
wave photonic sensor. 
The evanescent wave is the main mechanism to detect the effective index changes 
of the medium in a sensing process. Due to its propagation principle, local changes 
of the effective index caused by the presence of the biomolecules on the surface of 
the photonic structure are responsible of changes of the optical guiding properties. 
These changes are related to the sizes and concentrations of the target biomolecules, 
thus yielding to a quantitative signal. Note that selectivity is provided by the 
bioreceptor layer immobilized on the surface of the chip (e.g., chemical receptor, 
nucleic acids, aptamers, antibodies, etc.). 
Photonic biosensors based on evanescent wave detection have demonstrated their 
outstanding properties, such as an extremely high sensitivity for the direct 
measurement of biomolecular interactions, in real-time and in label-free schemes. 
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In order to convert the effective index variations into a measurable signal such as 
intensity or frequency variations, different configurations of photonic structures 
have been developed. Among the most common configurations, we can find ring 
resonators (Sun and Fan, 2011), Mach Zehnder interferometers (Washburn and 
Bailey, 2011) and periodic structures (Garcia et al., 2008) as depicted in figure 1.7. 
 
Figure 1.7. A: Ring resonator, B: Mach Zehnder interferometer and C: periodic 
photonic structure. 
From these photonic sensing configurations, those based on periodic configurations 
are showing an increasing interest because they offer several advantages such as 
robustness, high sensitivity and easy mass nanofabrication that leads to low-cost 
photonic sensing chips. Periodic photonic structures, which are sometimes referred 
to as photonic crystals or as photonic bandgap (PBG) structures, can exhibit what 
is known as photonic bandgap (PBG): a range of wavelengths in which light 
propagation is not allowed due to that periodicity of the structure. For sensing 
purposes, the position of the PBG is shifted when a target analyte/substance 
interacts with the structure due to the local variation of the refractive index, as it is 
schematically depicted in figure 1.8. Hence, by monitoring the evolution of the PBG 
position, we obtain the sensing information. Additionally, note that these periodic 
structures exhibit the so-called slow wave effect (Povinelli et al., 2005), which leads 
to a higher interaction between the optical wave and the target analytes/substances, 





Figure 1.8. Schematic representation of the operation principle of an evanescent 
wave biosensor based on PBG sensing structures. In the initial state (1), the PBG 
is located at a certain position; then, the PBG will shift when the target 
analytes/substances are detected (2). 
In this PhD Thesis, we have made use of 1D periodic photonic structures, as those 
previously depicted in figure 1.8. This type of configuration has been selected 
because it allows creating the PBG structure by simply periodically introducing 
straight transversal elements in a single mode optical waveguide, thus reducing the 
complexity in comparison with other 2D or 3D periodic configurations. 
 
1.4. Surface functionalization 
To enhance the interaction between the evanescent wave and the target 
analytes/substances, the functionalization of the photonic sensor surface is a crucial 
step. For example, the thinner the bioreceptor layer the higher the wave-target 
interaction, thus leading to an enhancement of the sensitivity, as schematically 
depicted in figure 1.9. As previously mentioned, the evanescent field is 
characterized by an exponential decay from the surface. This causes a strong 
dependence of the sensitivity with the distance of the target analyte from the 
structure surface. Since the biorecognition layer represents a new layer formed on 
the sensor surface, which separates the target analyte from such surface, the 
interaction between the evanescent wave and the target analyte is weaker as the 
thickness of the biorecognition layer increases. Some kinds of biofunctionalization 
techniques require several biofunctionalization steps, deterring from obtaining a 
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thin biolayer and leading to a weaker interaction, thus making the detection signal 
to be minimal or even not measurable. 
 
Figure 1.9. (A) Maximal interaction between the evanescent wave and the target 
analytes due to the creation of a thinner recognition layer, which leads to a 
higher sensing signal. (B) Lower interaction between the evanescent wave and 
the target analytes due to the creation of a thicker recognition layer, which leads 
to a smaller sensing signal. 
Among the different procedures for the biofunctionalization of biosensing 
structures, covalent strategies for the immobilization of bioreceptors provide 
several advantages in terms of nonspecific interactions restriction, robustness in the 
surface attachment and thickness reduction of the recognition layer comparing to 
other strategies based on physical adsorption (Phaner-Goutorbe et al., 2011). Here, 
for a covalently immobilization performance, it is necessary to design several 
surface modifications routes taking into account the chemical nature of the surface 
and depending on the final objective, the kind of the link between the surface and 
the biomolecule (i.e. through the functional groups of the biomolecule such as Lys, 
Cys amino acids, carboxyl groups ...) However, covalent surface functionalization 
strategy is more complex than physical adsorption, involving in our case, the 
modification of the silicon on insulator (SOI) sensor surface by the incorporation 
of functional groups able to react with the bioreceptors. Among these functional 
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groups, those provided by organosilanes are the most suitable candidates in order 
to conjugate bioreceptors to glass or similar surfaces (Mujika et al., 2009; Sieval et 
al., 1998). Several strategies to provide silicon-based surfaces with different 
terminals groups have been reported in the bibliography, as for example those based 
on a trifluoroethanol ester and the subsequent thermal acid hydrolysis, those based 
on the attachment of a photocleavable ester and subsequent photochemical cleavage 
(Sieval et al., 1998), or those based on the attachment of long chain monolayers 
(Cricenti et al., n.d.). 
Silanization methods are the most common ways to covalently modify silicon-
based surfaces in order to selectively attach the bioreceptors and it is much shorter 
in time than the EDC-NHS protocol for instance. Silane-based surface self-
assemblies are extensively reviewed in the literature (Haensch et al., 2010), being 
trialcoxysilanes such as 3-aminopropyltriethoxy silane (APTES) and 3-
trimetoxysilyl propyl methacrylate silane (MTPS) those mostly used and reported 
in the literature for liquid-phase surface functionalization (Halliwell and Cass, 
2001; Kim et al., 2009). However, the use of anhydrous solvents in these 
silanization strategies may lead to some undesirable effects, as for example the 
polymerization occurring at the free silanol in the solution and/or the silicon 
surface, altering the thickness of the silane layer, leading to more heterogeneous 
and irreproducible silane layer (Kim et al., 2009). 
In this PhD work, we have made use of the thiol-ene coupling (TEC) reaction for 
the biofunctionalization of the photonic sensing chips using half antibodies as 
bioreceptors. First, SOI surface was silanized to introduce the needed functional 
groups for a covalent attachment to the bioreceptor. In our case, we use an 
organosilane in order to introduce the functional groups over the SOI surface 
(Vinyl, alquinyl, acrylate, thiol, ...). Then, the covalent attachment of the 
bioreceptor to the chemically modified SOI surface is carried out by means of a 
click-chemistry reaction which is the thiol-ene reaction. From here, the need of 
thiolated bioreceptors and vinylated SOI surface or vice versa.  
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As it is a click chemistry kind of reaction, TEC is highly effective and does not 
generate side sub-products. TEC reaction is initiated by UV light which induces the 
formation of thiol radicals, which reacts with a carbon-carbon double bond (sp2 
hybridization) leading to a thioether. Moreover, it can be performed in aqueous 
media, making it ideal for the use of biomolecules. This feature makes the TEC 
reaction a highly interesting methodology to covalently immobilize the 
biomolecules for its use on photonic biosensing surfaces. 
From the biomolecules employed for the biosensing, the immunoglobulin G (IgG) 
antibodies are the most prominent ones. They are formed by four subunits, two 
heavy protein chains (H) and two light protein chains (L) separated in two halves. 
Those two halves are connected in the middle through the hinge region by means 
of disulfide bonds whose number depends on the species and the subclass of the 
antibody  (Vidarsson et al., 2014). Note that IgGs immobilization is a decisive 
milestone in the development of a biosensor to detect analytes such as proteins. 
Another key parameter for the biofunctionalization with IgGs is their oriented 
immobilization, since antibodies paratopes must be well oriented and available for 
the target protein to be captured. 
Besides the whole antibody, fragments such as Fab and scFab may successfully be 
employed as probes for proteins biosensing (Crivianu-Gaita et al., 2015; Crivianu-
Gaita and Thompson, 2016). In our context, for the purpose of using the previously 
mentioned TEC approach conserving an oriented capture site and lower distance 
from the sensing surface, we consider half antibodies as capture probes to 
covalently attach to the vinylated surface. To this aim, the disulfide bridge of the 
hinge region should be selectively reduced in this region resulting into two half 
antibodies with free thiols (Makaraviciute et al., 2016). Then, the use of the UV 
light induces the TEC reaction englobing the exposed sulfhydryl (SH) groups in the 
half IgG and the available alkene of the triethoxyvinylsilane (TEVS) functionalized 
PBG sensing surface. This allows an oriented immobilization of the half antibodies 
with a reduced distance between the capture probe and the photonic sensing surface. 
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Figure 1.10 schematically depicts the half IgG to TEVS-activated silicon surface 
functionalization protocol. 
 
Figure 1.10. (a) First, the IgG is reduced in order to obtain two half IgGs with 
available SH moieties. (b) The photocatalyzed TEC reaction is employed to 
induce the reaction between the available SH groups of the half IgGs and the 
alkene groups on the TEVS-silanized surface in order to covalently attach them 
to the sensing surface. 
 
1.5. Framework 
This PhD Thesis has been carried out at the Nanophotonics Technology Center of 
the Universitat Politècnica de València (UPV-NTC) in a very close collaboration 
with the Molecular Recognition group (UPV-SYM) in the frame of the Horizon 
2020 European project PHOCNOSIS (Advanced nanophotonic point-of-care 
analysis device for fast and early diagnosis of cardiovascular diseases). The aim of 
the PHOCNOSIS project is the development of a highly sensitive, compact and low 
cost POCT device combining nanophotonic and microfluidic technologies for a 
non-invasive early diagnosis of CVD. Therefore, the novel technology to be 
developed in the PHOCNOSIS project would allow a more sensitive, robust and 
selective analysis for improved clinical decisions through an early and fast 
diagnosis of CVD at a reduced cost, thus allowing several opportunities to the 
effective implementation of high-throughput screening programs. This leads to 
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better health outcomes, since the proper treatment/response can be applied to the 
patient in an earlier stage and will contribute to the sustainability of the healthcare 
system by decreasing the expenditure associated to inappropriate pharmaceutical 
treatments and with hospitalization. Moreover, this analysis device might also be 
used for its application in the monitoring and assessment of the therapeutic response 
of a patient, yielding to the practical implementation of the so-called “personalized 
medicine”. 
Within the PHOCNOSIS project, nanophotonic biosensors based on PBG sensing 
structures are proposed. The high sensitivity provided by nanophotonic sensing 
technology would allow detecting very low concentrations of the targeted 
biomarkers, with detection limit (LOD) values in the range of 1 μg/L (1 ng/mL), 
making use of sensing structures with an extremely reduced size (only few hundreds 
of μm2, meaning that we can have even thousands of sensing structures on a single 
chip of few mm2 for a highly multiplexed assay). However, these LOD values will 
not be enough for the detection of some biomarkers concentrations that need to be 
detected for the confident diagnosis of CVD at an early stage (in the ng/L (=pg/mL) 
range). So, how will we deal with this issue? 
In order to reach those levels, the nanophotonic sensors will be combined with a 
novel micro-/nanofluidic flow control system in development by one of the 
PHOCNOSIS consortium members. It is based on a depletion zone isotachophoretic 
(dz-ITP) filter. This micro-/nanofluidic system will be used to separate, purify and 
increase the effective concentration of the targeted biomarkers by a factor greater 
than 1000x. Therefore, the combination of this micro-/nanofluidic flow control 
system with the nanophotonic sensing structures would allow obtaining a final 
analysis device providing a DL below 1 ng/L (= 1 pg/mL), as required clinically. 
 
1.6. Structure of the Thesis 
After a general introduction of the Thesis frame in chapter 1, chapter 2 presents a 
theoretical and computational study carried out to identify the binding sites for the 
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cardiac Troponin I (cTnI) and for its antibody (anticTnI). Then, molecular docking 
has been used to test the availability of the system. This study was enriched with a 
computational study of the selectivity of the anticTnI towards cTnI versus the 
skeletal Troponin I (sTnI) which is considered the principal interferent for this 
biomarker. The aim of this study is to demonstrate that a computational binding 
study is highly interesting to complement and justify the laboratory assays and 
results. 
Chapter 3 presents a study of the functionalization of the photonic sensing 
structures using half antibodies. Several chemical functionalization trials have been 
performed and characterized in microarray configuration in order to optimize the 
biofunctionalization of the photonic chips. Characterization techniques such as 
Water Angle Contact (WCA), Atomic Force Microscope (AFM), Scanning 
Electron Microscope (SEM), Infrared Resonance Absorbance Spectroscopy 
(IRRAS) and Ellipsometry were handled to characterize the functionalized surface 
and verify that the biofunctionalization process is adequate before transferring it to 
the photonic chips. Then, PBG sensing structures were nanofabricated in our center 
clean room facilities and the biofunctionalization process with the half antibodies 
was carried out in-flow in order to monitor in real-time the UV light assisted 
immobilization of the bioreceptors when using the TEC reaction. 
In chapter 4, and after a Scanning Near-field Optical Microscope (SNOM) 
characterization study to verify the optimal evanescent wave behavior of the 
photonic structures, and once the surface chemical functionalization has been 
optimized, a covalent biofunctionalization method using half antibodies was 
undertaken. The first system chosen was Bovine Serum Albumin (BSA)/anti 
Bovine Serum Albumin (antiBSA) since it is a model system already optimized on 
microarray. Once the biofunctionalization was optimized in microarray, first 
detection assays by means of PBG structures were performed successfully. Then, a 
different biofunctionalization protocol based on protein G physical adsorption was 
employed over the PBG sensors for the cTnT detection performance in order to 
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reach the required CVD biomarkers detection at several concentrations depending 
on their required concentration ranges. 
Finally, chapter 5 is dedicated to general conclusions and future steps to enhance 
and fulfill the missing aspects for the final device performance.  
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Computational study of the 
cardiac troponin I 
interaction  
2.1. Introduction 
In the myocardial infarction case, a breakage of the cardiac troponin complex takes 
place, leading to the release of the troponin subunits (cTnT, cTnI and cTnC) to the 
blood stream. Thereby, the levels of these cardiac troponin subunits in blood can be 
used as an indicator of myocardial damage. However, troponin is also found in the 
skeletal muscle, where it is also in charge of controlling the muscle contraction-
relaxation cycle (Gordon et al., 2000). And as for the cTn, skeletal troponin (sTn) 
subunits (sTnT, sTnI and sTnC) are also released to the blood stream when the 
myofilaments of the skeletal muscle are damaged. Due to the similarity between 
cardiac and skeletal troponin, sTn subunits may interfere in the detection of cTn 
ones, thus limiting the utility of cTn detection (Eriksson et al., 2003). 
Previous works indicate that, from the three cTn subunits, the utility of cTnC for 
cardiac damage diagnosis is limited by the fact that it presents the same structure 
than sTnC, with the only difference of the number of Ca2+ binding sites (Yang et 
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al., 2009). Regarding TnT and TnI subunits, cTnT presents several specific cardiac 
isoforms whereas cTnI presents only one. From here, their use in cardiac diagnostic 
and prognostic applications (Collinson et al., 2015). 
Several comparative studies between cTnT cardiac isoforms and cTnI specific 
cardiac isoform have been carried out, concluding that cTnI exhibits a higher 
specificity and accuracy than cTnT for the diagnosis of acute myocardial infarction 
at its early stage (Apple et al., 2012). Therefore, cTnI has become the current gold-
standard biomarker in clinical diagnosis for the identification of acute heart failures. 
However, it may present a high cross reactivity with the sTnI regarding the 
interaction with cTnI antibody. 
Within this context, in this chapter we perform a computational interaction study of 
a cTnI antibody (anticTnI) with cTnI and sTnI. This study allows obtaining 
information about the biochemical interactions between them and to 
computationally compare the binding performance and the selectivity of the 
anticTnI towards cTnI versus sTnI rather than experimentally. This information can 
be relevant for the development of analysis systems for myocardial failure diagnosis 
based on cTnI detection. First, FTSite and FTMap software were employed to 
analyze the structure of the targets (cTnI and sTnI) and the antibody binding 
fragment (Fab) structure. After the consideration of several amount of 
conformations for cTnI and sTnI (more than a hundred), their most stable 
conformations (i.e., whom possess the lowest total energy) were chosen to 
determine and characterize the binding regions of these molecules. Next, pyDock 
and FTDock were used to study the molecular docking of the cTnI-anticTnI and 
sTnI-anticTnI complexes to determine their most stable predicted conformations. 
Energies and interactions results provided by the simulations tools for these 
predicted conformations allowed us to determine the affinity for each of these 
complexes and thus to perform the selectivity study. In this study, the temperature 
is considered at 0 K in vacuum and employing the rigid mode of the molecules to 




2.2. Binding sites identification 
The identification of the binding sites is a long-lasting problem to solve for a wide 
range of applications such as for proteins, antibodies or for new drugs design. 
Therefore, an accurate method for binding sites identification is of a high interest. 
The binding sites of proteins contain the so-called hot spots, specific regions that 
provide major contributions to the binding free energy. These hot spots are 
constituted by one or several amino acids that are more likely to bind small 
molecule probes and compounds with high affinity, and hence are the prime targets 
in several fields such as immunology or drugs design (Yuan et al., 2013). 
Experimental techniques to determine these interactions occurring within the 
binding regions, e.g., nuclear magnetic resonance or X-ray crystallography, are 
highly expensive, time consuming and can be limited by the physical constraints of 
the protein-solvent system (Allen et al., 1996). Within this context, computational 
methods allows characterizing these binding regions numerically rather than 
experimentally so as to predict their probability of recognition and binding with 
other molecules (Katchalski-Katzir et al., 1992). 
FTSite web server is emerging as a potential solution for this issue, since it is based 
on experimental evidence that ligand binding sites also bind other small organic 
molecules of various properties such as polarity, size and shapes. FTSite algorithm 
does not depend on any evolutionary or statistical information. Nevertheless, it may 
achieve very high experimental accuracy, since it is based on established test sets 
that have been used for many other binding sites prediction methodologies (Ngan 
et al., 2012). FTSite is based on the observation that a binding site of a molecule 
(i.e., protein) includes a potential main hot spot and other secondary spots close 
enough to be reached by a ligand binding at the main hot spot (Hall et al., n.d.; Ngan 
et al., 2012). The premise behind is that ligand binding sites also binds small 
molecules of various shapes and polarity as observed by NMR and X-ray 
crystallography experiments (Brenke et al., 2009), so it performs a computational 
mapping of individual places each of different small molecular probe on a dense 
grid around the protein and finds favorable positions using empirical free energy 
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functions. The probes are clustered, and the clusters are ranked on the basis of their 
free energy average. 
Another computational tool similar to FTSite that has been used in this work for the 
identification of binding sites is FTMap. FTMap web server presents high potential 
for determining and characterizing binding hot spots using only computational 
approaches that may complement the experimental methods, hence avoiding their 
economical and time drawbacks. FTMap is a close computational analogue of the 
NMR or X-ray crystallography-based screening experiments. A direct binding hot 
spots information and molecules druggability are provided by FTMap, and can be 
used for extending fragment hits up to larger ligands (Brenke et al., 2009a). 
In the FTMap approach, the server method consists on the distribution of up to 16 
cluster probes (acetone, acetaldehyde, acetamide, acetonitrile, benzaldehyde, 
benzene, cyclohexane, dimethyl ether, N, N dimethyl formamide, methylamine, 
phenol and urea). By varying size, shape and polarity on the target macromolecule 
surface, it finds the most propitious positions for each probe type before clustering 
the probes and ranking the clusters depending on their average energy (Hall et al., 
n.d.). Those probes are used for an initial rigid body docking against the entire 
protein surface. The “FT” of FTMap stands for the use of Fast Fourier Transform 
(FFT) methods to quickly sample billions of probe positions while calculating 
accurate energies based on a robust energy expression (attractive and repulsive 
Van-der-Waals terms, electrostatic interaction energies and desolvation energies) 
based on translational (0.8 Å translation) and rotational (500 rotations) motion for 
each location fastening the calculations (Brenke et al., 2009b; Hall et al., 2011; 
Kozakov et al., 2011). Following the docking of each probe, thousands of poses are 
energy-minimized and clustered based on proximity. The algorithm generates 
bound positions for each of those probes using rigid body docking and samples 
billions of the available probe positions. Here, regions that bind a high variety of 
the clusters probes are called the consensus sites, and from these consensus sites, 
the site containing the higher number of probes is the main hot spot. FTMap ranks 
the consensus clusters by the number of the bonded contacts between the amino 
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acids of the proteins consensus sites and all cluster probes rather than by their 
number, since the former approach provides slightly better binding sites prediction 
(Ngan et al., 2012b). 
The required input for FTSite and FTMap calculations is an X-ray or NMR structure 
of the molecule (DNA, protein, …). X-ray structures of the molecules used in this 
study were obtained from the Research Collaboratory for Structural Bioinformatics 
(RCSB) protein data bank (pdb) (www.rcsb.org). 
So here, the use of two similar computational based tools for the binding sites 
identification allows us to demonstrate that both computational methods are 
accurate if the results are in match, so the computational approach can be a useful 
strategy to address more rational biosensor development narrowing the 
experimental campaign.  
 
2.3. Binding sites results 
The IDs of the sTnI and the anticTnI structures from pdb are 1VDI and 4P48, 
respectively. Note that the only available anticTnI on the database is the polyclonal 
one belonging to chicken and hence the only possible one to perform this study. For 
the case of the cTnI, its sequence was extracted from the whole cardiac troponin 
complex provided by RCSB with the ID 4Y99. Before their application, those 
molecules were purified by removing those atoms not corresponding with the 
molecules of interest from the original pdb files and that might be present in the 
downloaded models (water and ions). 
First, the binding sites on the molecules surface were determined for the cTnI, sTnI 
and anticTnI. Even when the structure of a molecule is determined by 
crystallography in a complex with a ligand, a complete description of its binding 
sites with that ligand cannot be determined experimentally because complex 
structures may not fully exploit the overall properties of the binding site. Moreover, 
knowledge of the possible binding sites in the structure of a molecule also enables 
us to analyze and classify them through their binding sites profiles. Figure 2.1 
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shows the chosen binding sites for cTnI, sTnI and anticTnI determined using 
FTSite. The 3D visualizations were carried out by pyMol software. FTSite also 
provides the amino acids sequences forming the binding sites as depicted in Table 
2.1. Note that the represented results belong to the most stable conformations. 
            
Figure 2.1. FTSite results showing the binding sites (colored grids) of (left) 
cTnI, (center) sTnI and (right) Fab region of the anticTnI. The visualization has 
been done using PyMOL. 
 
Table 2.1. Complete description of the amino-acids sequences forming the binding sites given by 
FTSite for cTnI, sTnI and Fab region of the anticTnI. 










Met134; Arg137; Ala138; 
Asn139; Leu140; Lys141, 
Gln142; Val143; Lys145; 
Glu149; Glu151; Lys152; 
Asp153; Leu154; Arg155; 
Asp156; Gly158; Asp159; 
Trp160; Arg161; Asn163; 
Glu165; Ser168; Gly169; 
Met170; Gly172; Arg173; 
Lys174; Phe177 
Leu2; Arg25; Tyr26; Tyr27; Asp28; 
Ala44; Pro45; Thr47; Glu51; Lys54; 
Asn58; Asp93; Asp94; Asn95; 
Asn97; Pro98; Thr99, Phe101; 
Gly102; Leu130; Leu132; Gly172; 
Leu173; Glu174; Trp175; Gln180; 
Gly185; Ala190; Ala191; Lys226; 
Asp227; Ser229; Ser230; Asp231; 




Once the binding sites sequences were obtained using FTSite, FTMap was executed 
to determine the number of H-bond interactions between the amino acids 
comprising the binding site and the organic probe molecules tested by FTMap. 
Tables 2.2, 2.3 and 2.4 show the H-bond interactions with the probe molecules for 
cTnI, sTnI and anticTnI, respectively. The first column lists the amino acid number 
within the binding site, the second lists the amino acid 3-letter code and the third 
column lists the number of H-bond contacts between the amino acids and the probe 
molecules. 
 
Table 2.2. cTnI H-bond interaction results between the amino acids from the binding site and the 
probe molecules as identified by FTMap. 
  cTnI amino acid number Amino acid 3-letter code          Number of H-bond contacts 
49; 52; 72; 79; 80;  
81; 82; 83; 84; 93; 
 99; 100; 103; 104; 107; 
 110; 111; 115 
Leu; Leu; Lys; Arg; Ala;  
Gln; Pro; Leu; Glu; Leu;  
Gln; Leu; Arg; Val; Val;  
Glu; Arg; Glu 
66; 15; 30; 556; 26; 
1510; 174; 119; 918; 490;  
26; 761; 531; 23; 830; 
 431; 207; 20 
 
Table 2.3. sTnI H-bond interaction results between the amino acids from the binding site and the 
probe molecules as identified by FTMap. 
sTnI amino acid number Amino acid 3-letter code           Number of H-bond contacts 
134; 137; 138; 139; 140; 
141; 142; 143; 145; 149; 
151; 152; 153; 154; 155; 
156; 158; 159; 160; 161; 
163; 165; 168; 169; 170; 
172; 173; 174; 177 
Met; Arg; Ala; Asn; Leu; 
Lys; Gln; Val; Lys; Glu; 
Glu; Lys; Asp; Leu; Arg; 
Asp; Gly; Asp; Trp; Arg; 
Asn; Glu; Ser; Gly; Met; 
Gly; Arg; Lys; Phe 
102; 1; 5; 6; 13; 
133; 84; 63; 1094; 60; 
2014; 11; 3708; 2; 883; 
2; 3; 3; 135; 165; 
5; 738; 1041; 981; 1020; 




Table 2.4. anticTnI H-bond interaction results between the amino acids from the binding site and 
the probe molecules as identified by FTMap. 
anticTnI amino acid number Amino acid 3-letter code                              Number of H-bond 
contacts 
2; 25; 26; 27; 28; 
44; 45; 47; 51; 54; 
58; 93; 94; 95; 97; 
98; 99; 101; 102; 
130; 132; 172; 173; 174; 
175; 180; 185; 190; 
191; 226; 227; 229; 230; 
231; 234; 237; 238; 
240; 242; 244 
Leu; Arg; Tyr; Tyr; Asp; 
Ala; Pro; Thr; Glu; Lys; 
Asn; Asp; Asp; Asn; Asn; 
Pro; Thr; Phe; Gly; 
Leu; Leu; Gly; Leu; Glu; 
Trp; Gln; Gly; Ala; 
Ala; Lys; Asp; Ser; Ser; 
Asp; Tyr; Asp; Ser; 
Asp; Trp; His 
19; 151; 233; 517; 1; 
2; 693; 2676; 233; 11; 
369; 7; 282; 48; 108; 
338; 401; 1804; 171; 
43; 215; 33; 646; 39; 
2220; 395; 14; 923; 
66; 24; 6; 1165; 48; 
82; 1392; 816; 727; 
1052; 2228; 8 
By now, from the more stable conformations of the studied molecules, FTSite 
provides the amino-acid sequences forming the binding sites and FTMap provides 
from these binding sites the amino-acids who have a greater number of H-bonds 
from the interaction with the probes. 
Once the binding sites and hotspots are identified, the next step is studying the 
docking performance between cTnI and anticTnI from a side and sTnI with anticTnI 
from the other, in order to determine the most propense docked complexes and to 
identify the more desirable protein to bind the anticTnI. 
 
2.4. Molecular docking 
As for binding sites, an accurate scoring of rigid-body docking orientations 
represents one of the major difficulties in protein-receptor docking predictions. 
Good discrimination of docking conformations from earliest stages is considered 
an essential milestone before applying more costly refinement to the correct 
docking solutions. Here, we have explored simple approaches to score the protein-
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protein dockings implemented in a web server program named pyDock. pyDock is 
based on Coulombic electrostatics with dielectric constant distance dependence and 
implicit desolvation energy with atomic solvation parameters for protein-protein 
docking. pyDock is able to detect a near native solution from thousands (more than 
12.000) docking poses and place it within the top 100 lowest energy docking 
solutions in a large variety of cases (about 56%), without any additional propitious 
to confusing information. This makes pyDock a fast tool for better understanding 
and evaluation of a large range protein-protein docking configurations (Villar et al., 
2014). Another parameter to consider is the Van-der-Waals energy. Here, this 
energy in the scoring of docking configurations is based on the 6-12 Lennard-Jones 
potential with atomic parameters from AMBER 94 force field (Cornell et al., 1995). 
As with Coulombic electrostatic potentials, to avoid the noise from the protein-
protein docking surfaces, the interatomic Van-der-Waals energy has been truncated 
to a maximum of 1 Kcal.mol-1. From the other side, FTDock was launched in 
parallel. FTDock is based on Fast Fourier Transform (FFT), what is used to speed 
up the calculations by performing them within the Fourier space. Billions of 
different conformations are examined during this process, from which 10,000 are 
retained. The scoring criteria for retention of a possible complex is principally based 
on shape complementarity and also incorporates approximate electrostatics scoring 
(Li, 2006). Note that for this work, the docking algorithm FTDock was used in order 
to double check the viability of pyDock, since the same resulting prediction may 
confirm the correct predicted results. 
 
2.5. Molecular docking results 
After the identification and mapping of binding sites and the interactions of their 
constitutive amino acids sequences, the next step is studying the molecular docking 
for the cTnI and the sTnI to the anticTnI. This process of docking provides the 
specific interactions details between the proteins and the antibody Fab region taking 
into account spatial distribution, Van-der-Waals interactions and rotational 
restrictions, among others. For the docking analysis, FTDock and pyDock were 
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launched. FTDock generates several output pdb files with docking probabilities 
organized from the highest to the lowest probable one. On the other hand, pyDock 
generates several randomly located pdb files of the docked complexes, and these 
results are accompanied by other generated files describing energies, positions and 
angles that is the main key to organize the predicted complexes. The ranking of 
molecular docking complexes obtained with both methods are the same. Figure 2.2 
shows the docked complexes obtained for cTnI-anticTnI and sTnI-anticTnI. 
 
Figure 2.2. Most probable docked configurations of (left) cTnI-anticTnI and 
(right) sTnI-anticTnI complexes. Binding zones are highlighted with black 
circles. 
Table 2.5 shows the identified H-bond interactions for the cTnI-anticTnI and the 
sTnI-anticTnI complexes obtained using FTDock and pyDock. Three H-bonds are 
predicted for both complexes. However, while these H-bonds are involving three 
different amino acids for the cTnI-anticTnI complex, for the sTnI-anticTnI complex 
two of them are formed by the same amino acid from the sTnI (Glu149), what is 
translated into weaker H-bonds than for cTnI-anticTnI formed complex. This fact 
determines the higher affinity of anticTnI towards cTnI than sTnI. Having identified 
the most stable predicted structures, the formed cTnI-anticTnI and sTnI-anticTnI 
complexes were visualized using PyMOL to depict the specific interactions 
between the amino acids sequences previously identified (see figure 2.3). 
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Table 2.5. Identified H-bonds for the cTnI-anticTnI and the sTnI-anticTnI complexes identified 











Figure 2.3. Detailed 3D view of the (left) cTnI-anticTnI and (right) sTnI-
anticTnI docked complexes. H-bonds between the amino acids from the binding 
sites are depicted with dashed red lines and highlighted with black circles. 
Table 2.6 depicts the parameters describing the energies obtained from FTDock 
for the most stable docking configurations for the cTnI-anticTnI and sTnI-anticTnI 
complexes. We can see that the total energy of the cTnI-anticTnI complex is 
considerably lower than for the sTnI-anticTnI complex, what indicates a higher 
affinity of anticTnI towards cTnI than for sTnI. This confirms the lower affinity for 
the sTnI-anticTnI complex predicted from the H-bonds data previously shown in 
Table 2.5 and figure 2.3. 
Table 2.6. Energy data (Kcal/mol) for the most stable docked complexes for cTnI-anticTnI and 
sTnI-anticTnI. 
Complexes Electrostatic interaction Desolvation Van-der-Waals Total 
cTnI-anticTnI -11.866 -20.190 28.475 -29.208 




In this chapter, we have been able to determine the binding sites of cTnI, sTnI 
and anticTnI by using FTSite and FTMap. Then, the two troponins were docked 
with the anticTnI. From the results of energy and the formed hydrogen bonds, we 
have demonstrated that an affinity study can be performed computationally rather 
than experimentally, what can dramatically reduce the time and cost when 
developing immunosensing systems. To our knowledge, this is the first time that 
this kind of computational affinity study is performed for cardiac troponin I. The 
obtained computational affinity and selectivity results are highly important, since 
they compare the suitability of cTnI and its principal interferent sTnI, to bind 
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by a PBG biosensor 
 3.1. Introduction 
In this chapter, we develop an UV light-induced biofunctionalization protocol for 
the covalent immobilization of specific bioreceptors over silicon-based biosensing 
structures. The use of an UV light-induced biofunctionalization method allows a 
high resolution and spatially selective immobilization. A biofunctionalization 
protocol based on the thiol–ene coupling (TEC) reaction (Escorihuela et al., 2014), 
which occurs between thiol and vinyl groups under UV light excitation, has been 
used to immobilize thiol-terminated bioreceptors over vinyl-terminated SOI PBG 
sensing structures. 
Half-antibodies (hIgG) have been used as bioreceptors for their immobilization 
over the PBG sensing surface after a selective reduction protocol in the hinge region 
as schematized in chapter 1 (figure 1.10). This reductive protocol provides free thiol 
moieties available after the cleavage of their disulfide bridges, allowing us the 
binding of the half antibodies with oriented paratopes. Note that the use of 
immobilized hIgG with the biofunctionalization approach described above can also 
provide several significant benefits such as a higher surface coverage density, a 
lower thickness of the biorecognition layer and the previously mentioned proper 
orientation of the antibodies binding sites. The biofunctionalization of the silicon-
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based sensing structures within the photonic chip has been carried out in-flow, 
while their responses were monitored in real-time, which has allowed us to 
experimentally confirm the photocatalytic reaction required to immobilize the 
bioreceptors using the TEC approach. 
 
3.2. PBG sensors nanofabrication 
SOI is the most employed materials technology in a wide range of nanofabrication 
approaches and especially in nanophotonics, due to its compatibility with CMOS 
(Complementary Metal Oxide Semiconductor) fabrication processes from the 
microelectronics industry. The micro and nanophotonics components developed 
operate in the infrared (near infrared), usually with a wavelength around 1550 nm. 
Briefly, the SOI wafer used in this work consists on a 220 nm thick layer of silicon 
over a 3 μm layer of silicon oxide over around 675 μm of silicon that provides more 
consistency to the whole SOI wafer. Figure 3.1 depicts a simplified scheme of the 
SOI layers distribution. 
 
Figure 3.1. Layers distributions of the SOI wafer. 
In SOI nanofabricated structures, light is highly confined within the top silicon layer 
which is highly valuable for photonic structures fabrication. The high confinement 
of the light is due to the high variation of the refractive index (RI) between the 
silicon oxide lower cladding (RI=1.45), the silicon core layer (RI=3.46) and the air 
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upper cladding (RI=1). Light propagation on a SOI structure is schematized in 
figure 3.2. 
 
Figure 3.2. Light propagation scheme in a SOI nanofabricated structure. 
Another advantage of SOI integrated photonics is the extremely size reduction, 
which leads to the integration of a large amount of sensing structures in a single 
SOI piece called photonic chip, thus allowing the possibility to detect 
simultaneously several biomarkers in a multiplexed chip. Also, mass production 
nanotechnology is cost effective. Hence, the achievement of an affordable 
integrated POCT device. The PBG structures used in this work consist on a 1D 
silicon periodic structure created by the introduction of straight transversal elements 
in a conventional single mode waveguide, as schematically depicted in figure 3.3, 
where the main parameters of the structure are also depicted (Garcia et al., 2008; 
Yablonovitch, 1993). 
 




The design of these PBG structures has been carried out by means of Plane Wave 
Expansion (PWE) (Johnson and Joannopoulos, 2002) and Finite-Difference Time-
Domain (FDTD) (Namiki, 1999) simulations, which were carried out using MIT 
Photonic Bands (MPB) (Kuchinsky et al., 2002) and CST Microwave Studio, 
respectively. PWE simulations were used to obtain the band diagrams for the 
different potential configurations of the PBG periodic structure considering only 
TE-like modes with an even in-plane symmetry, as PBGs will only appear for that 
polarization and only that in-plane symmetry will be excited by the access single 
mode waveguide. 
From these simulations, we determined those configurations having their PBG 
edges located in the 1500-1600 nm wavelength range for air and water upper 
cladding. For those configurations, FDTD simulations were carried out to obtain 
their transmission spectral response to select the configuration showing a sharper 
and deeper PBG edge. The selected parameters for the designed silicon PBG 
structure are: height h = 220 nm, waveguide width w = 450 nm, period a = 380 nm, 
transversal elements length we = 1500 nm and transversal elements width wi varying 
from 80 to 140 nm to tune the position of the PBGs. Figure 3.4 shows the band 
diagrams and the simulated transmission spectra of one of those selected 
configurations when considering air and water upper claddings. As it can be 
observed, two PBGs appear for this configuration; that appearing between the 





Figure 3.4. (Left) Band diagram and (Right) simulated transmission spectra 
calculated for the selected configuration of the PBG structure with wi = 120 nm 
(red line for an air upper cladding and blue line for a water upper cladding). The 
red shaded regions depict the two PBGs appearing for this structure for an air 
upper cladding. The gray shaded region in the band diagram correspond to the 
modes under the light cone of the SiO2 lower cladding and thus being leaky. 
The SOI photonic sensing chip has been created in our clean room facilities using 
E-Beam Lithography EBL nanofabrication technology (see figure 3.5). After the 
deposition of a layer of hydrogen silsesquioxane (HSQ) photoresist, the desired 
structures layout was exposed using EBL. In order to transfer the pattern to the 
silicon layer, a dry etching using inductively coupled plasma etching was carried 
out. Here, the remaining photoresist acted as a mask, protecting the covered silicon, 
while the uncovered part was etched. Finally, the photoresist was removed, and the 




Figure 3.5. Schematic description of the nanofabrication process based on 
Electron Beam Lithography (EBL). 
Figure 3.6 shows several pictures of the fabricated SOI photonic chip. It contains 
several PBG structures that are used as sensing elements. In these structures, the 
introduction of a periodic modulation in the refractive index of the photonic 
structure gives rise to the appearance of a rejected spectral band, the so-called PBG 
(Povinelli et al., 2005), whose position will depend on the refractive index of the 
surrounding medium with a high sensitivity. The SOI photonic chip contains 4 
groups of 4 PBG sensing structures in each group (16 sensing structures/chip) 
whose structural parameters are height h = 220 nm, waveguide width w = 450 nm, 
period a = 380 nm, transversal elements length we = 1500 nm, and transversal 
elements widths ranging from wi = 80 nm to 140 nm (wi = 80, 100, 120, and 140 
nm for each of the PBG structures within each group). These structural parameters 
provide PBG edges located in the 1550 nm wavelength range, where our 
experimental characterization equipment operates. The separation between the 
sensor groups is 1.5 mm in the transversal direction of the photonic chip. The chip 
is accessed at the input and the output via 70 nm-deep shallow etch 1D grating 
couplers. Finally, to provide physical robustness to the fabricated chip with the 
photonic structures, the chip is covered with a 400 nm-thick SiO2 upper cladding 
and a 400 µm-wide channel is opened on it using UV lithography to strip off the 




Figure 3.6. (Left) Image of the photonic chip fabricated in SOI technology. The 
circle depicts the position of one of the PBG sensor groups. (Center) Optical 
microscope image of a PBG sensor group. The fifth structure on the top up of 
the group corresponds to a reference waveguide. The channel opened on the 
SiO2 upper cladding can also be observed. The circle depicts an individual PBG 
sensing structure. (Right) Scanning Electron Microscope (SEM) image of a 
fabricated PBG sensing structure. 
 
3.3. Surface chemistry 
As previously mentioned in chapter 1, a nanophotonic biosensor is based on the 
interaction between the evanescent wave and the target analytes. This exponential 
wave is more intense in the surface of the photonic structure and it weakens as the 
height increases. From here, the need of a highly thin chemical layer. 
Within this context, a trustworthy immobilization of bioreceptors is a crucial step 
over any surface sensor to achieve the highest sensing performance with the aim to 
analyze the target samples with any or minimal previous processing (González-
Guerrero et al., 2013). To achieve this, we have implemented a functionalization 
way for the covalent immobilization of the bioreceptors over the photonic sensing 
area. The proposed method consists in a silanization of the SOI chip surface by 
means of the Trietoxyvinylsilane (TEVS) which is a trialcoxysilane, usually used 
in toluene as solvent. Here, we present a novel silanization approach consisting in 
the use of TEVS in water. The use of water as carrier offers several advantages such 
as the avoid of the organic waste generation, the decrease of the cost and the most 
important, leading to the assembly of a compact and homogeneous layer. 
Furthermore, the cross-linking wards off when the conditions are optimal (TEVS 
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%, immersion time, pH, temperature and curing time). Once the silanization step is 
implemented, the next step is the immobilization of the bioreceptors. Here, we use 
a covalent linking strategy by employing half antibodies. After their moieties 
breakage by means of the tris(2-Carboxyethyl) phosphine (TCEP) for the selective 
reduction of the antibody within the hinge region to obtain free thiols, the TEC 
reaction is performed to immobilize the half antibodies to the surface via these free 
thiols. This allows the paratopes of the half antibody to be oriented in the sense of 
the solution containing the target analytes, which increases the recognition 
efficiency. UV-light is used to induce the reaction between free thiols from the half 
antibodies to the alkene groups on the chip surface (photo-catalysis), leading to the 
TEC chemistry reaction. It is noteworthy to remind that TEC is a type of click-
chemistry reaction, which are chemical process reactions that are high yielding, 
with atom economy, wide in scope and created only by products that can be 
removed without chromatography. Also, they are stereospecific, simple to perform 
and can be conducted in easily removable or benign solvents. Yielding to generate 
substances by joining small units together by means of heteroatom links (C-X-C), 
with the objective of expanding set of powerful and selective blocks that works in 
both small and large scale applications (Kolb et al., 2001). Note that cycloadditions, 
Diels-Alder are the more extensively, whereas Cu catalyzed azide cycloadditions is 
one of the most extended example of TEC reaction.  
TEC chemistry needs a high thermodynamic driving force, usually greater than 20 
Kcal/mol, difficultly achieved in normal conditions and hence the need of a 
catalytic reaction. Thus, the use of UV light that induces TEC chemistry reaction 
between the vinyl group of the TEVS and SH terminated half antibodies seems to 
be highly effective, selective and does not yields to side products generation, 
allowing the covalent attachment of the half antibodies to the vinyl groups of the 
SOI sensing surface. This biofunctionalization approach has been used to 
immobilize half immunoglobulins G (hIgG) to the surface of a vinyl-functionalized 
silicon-on-insulator nanophotonic sensing chip. The response of the sensing 
structures within the nanophotonic chip was monitored in real-time during the 
biofunctionalization process, which has allowed us to confirm that the 
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bioconjugation of the thiol-terminated bioreceptors onto the vinyl-activated sensing 
surface is only initiated under UV light photocatalysis. 
To immobilize the thiol-terminated bioreceptors onto the silicon-based sensors 
using the UV light-induced TEC reaction, the silicon-based photonic chip is first 
silanized using TEVS to obtain a vinyl-terminated compact layer upon its surface 
(Escorihuela et al., 2012). The silanization process consisted on immersing the SOI 
photonic chip in 1% TEVS in Milli-Q water (pH adjusted to 8 by adding 100 µL of 
1 M KOH in Milli-Q water) for 1 h, then curing it at 110 °C for 1 h for condensation 
and water excess evaporation before the final Milli-Q water rinse of the 
functionalized chip. Note that before performing the silanization process, the SOI 
photonic chip was cleaned in a piranha solution (H2SO4/H2O2: 1/3) for 20 min and 
then activated using O2 plasma for 10 min. 
 
Figure 3.7. Steps of the silanization process used to create a vinyl-terminated 








3.4. Surface characterization 
To characterize the initial silanization step, several characterization techniques 
were employed before and after performing it. First, the water contact angle (WCA) 
test indicates a significant increase of the hydrophobicity of the surface after 
performing the TEVS silanization from ~30° before to ~80° after silanization as 
shown in figure 3.8, which confirms the coverage of the SOI surface with the 
organosilane. Then, IRRAS (Infrared Reflection Absorption Spectroscopy) was 
employed to characterize the functional groups upon the surface (see figure 3.9). 
The spectral bands appearing at 1500 cm-1 corresponds C=CH whereas the Si-CH 
and the Si-O-Si appears at 1400 and 1200 cm-1 respectively. The spectral bands at 
3062 cm−1 and 3020 cm−1 correspond to the =C-H asymmetric and symmetric 
stretching vibrations for the vinyl groups of the TEVS organosilane, which 
confirms the presence of the vinyl groups upon SOI surface required to perform the 
proposed light-assisted immobilization of thiol-terminated probes. Finally, the 
topography of the surface before and after TEVS functionalization was 
characterized by means of AFM (Atomic Force Microscope) measurements. Figure 
3.10 demonstrates that a very low roughness is measured after performing the 
silanization process, which indicates a high homogeneity and compactness of the 
deposited TEVS layer. Therefore, all the characterization techniques employed 
confirm the adequate creation of the TEVS layer on the surface of the SOI chip. 
 
Figure 3.8. (Left) Water contact angle before silanization. (Right) Water contact 




Figure 3.9. Infrared reflection absorption spectroscopy (IRRAS) 
characterization results of the SOI chip after the TEVS silanization.  
 
Figure 3.10. Atomic force microscope (AFM) topography characterization of 
(left) the bare SOI surface and (right) the SOI surface after TEVS silanization. A 
very low roughness (in the sub-nm range) is measured for both surfaces. 
 
3.5. UV light-assisted immobilization of half antibodies 
IgGs or antibodies are nowadays the most dominant class of immunoglobulins 
employed in the biosensing field because of their high immune affinity to proteins. 
Antibody fragments are emerging also to be successfully employed as biosensing 
probes, since reductions such as mercaptoethylamine (MEA) and 
tris(2carboxyethyl) phosphine (TCEP) are protocols that allow obtaining those 
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fragments. When employing MEA reduction, an over reduction occurred and 
disulfide bridges are cleaved driving to a non-selective fragment cleavage, leading 
to loss of recognition property. In contrast, the TCEP protocol can be optimized in 
concentrations, time and temperature leading to the identification of the optimal 
conditions and hence the reach of the maximal number of half IgGs with the highest 
recognition capability with presence of reduced disulfide bonds within the hIgG 
moieties (Cline et al., 2004; Makaraviciute et al., 2016). 
The thiol-terminated bioreceptors used here are hIgG specific to bovine serum 
albumin (BSA). These rabbit half anti-BSA antibodies (haBSA) were obtained 
using TCEP reduction process consisting on the incubation (for 90 min at 37 °C) of 
the anti-BSA in acetate buffer (0.15 M sodium acetate, 0.01 M EDTA, 0.1 M 
sodium chloride, pH = 4.5) at 4 mg/mL concentration in the presence of 25 mM 
TCEP. The corresponding haBSA were purified by employing a 50 kDa centrifugal 
filter unit and the concentrations of the solutions were determined by employing a 
NanoDrop spectrophotometer. After this cleavage process, thiol groups from the 
disulfide bridges turn to be available on the resulting haBSA for their 
immobilization over the vinyl-terminated surface by means of UV light (254 nm) 
photocatalysis, as schematically depicted in figure 3.11. Further details about this 
TCEP reduction process can be found in (Alonso et al., 2018).  
 
Figure 3.11. Schematic representation of the process used for the UV light-
assisted covalent immobilization of the half anti-bovine serum albumin (haBSA) 
on the SOI sensors surface. 
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Once the proper silanization of the chip surface was confirmed, we performed 
fluorescence microarray tests on planar SOI surfaces to verify the proposed light-
assisted TEC immobilization protocol. To this aim, AlexaFluor 647-fluorophore 
labelled haBSA (haBSA*) at 20 µg/mL nanodrops volume were dropcasted over 
two different TEVS silanized SOI chips. One of those chips was irradiated with UV 
light (254 nm with a power of 6 mW/cm2) to induce the reaction between the vinyl 
groups on the surface and the thiol groups from the haBSA*, while the other chip 
was kept without UV light irradiation. Finally, both chips were thoroughly washed 
with phosphate buffered saline solution with Tween 20 (PBS-T) followed by a 
water washing before they were dried. Then the fluorescence was checked by a 
CCD camera. Figure 3.12 shows the fluorescence results for both chips, where we 
can clearly see that fluorescence is only observed for the chip being irradiated with 
UV light, thus confirming the UV-dependent nature of the biofunctionalization 
process. 
 
Figure 3.12. Fluorescence microarray measurements employing a CCD camera 
for: (A) TEVS silanized chip with deposited haBSA* at 20 µg/mL with no UV 
irradiation and (B) TEVS silanized chip with deposited haBSA* after 254 nm 




3.6. Experimental opto-fluidic setup 
In order to deliver the target sample over the chip, a microfluidic flow cell has been 
used. The microfluidic cell material is a relevant parameter, since the irregularity 
may lead to bubble air generation or leakage. The material should also be inert and 
versatile in order to path adaptation of the flow system to the experimental 
requirements. Within this context, several materials were considered, but 
polydimethylsiloxane (PDMS) exhibits several advantages. PDMS is an elastomer 
that has the ability to adopt the shape of the container and surface after curing, what 
allows to easily fabricate the microfluidic structures by soft lithography with good 
results, obtaining small drawbacks for the Lab-On-a Chip integration. Moreover, 
the material is biocompatible due to its inertness, low cost and ease of handle and 
fabricate. Additionally, PDMS is transparent which makes possible through in 
irradiation and the observation of the flow evolution through the fluidic system and 
detect in time any obstruction or leakage. For the microfluidic channel fabrication 
with PDMS, two principal steps are required: the creation of the mold and the 
transfer of the design to the PDMS. For the creation of the mold, it has been 
fabricated in a silicon wafer by patterning the microchannels in ``Sukhoy-8´´ 
polymer (SU-8), which is a negative photoresist with presence of eight epoxy 
groups by standard UV lithography. In our case, for the master mold design, we 
used a 50 μm thick SU-8, which leads to 50 μm height microchannel after 
lithography. The transfer of the design to the PDMS was done like following. First, 
a mixture of 90% PDMS and 10% curing agent weight were blended on a Petri. 
Then, it was degassed using a vacuum chamber to take off all air bubbles that may 
cause air leakage and/or obstructions into the final microfluidic channel. And 
finally, the master mold was covered with the PDMS and curing agent mixture and 
cured in a stove at 110ºC during 30 min. Then, the master mold is removed and the 
PDMS to Teflon tubing connections holes are perforated using a puncher and the 
tubes were connected to a syringe pump. Pumping assays using different solutions 
were performed to proof the microfluidic efficiency of the channels. 
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The ease of PDMS channels fabrication allows the handle of many channels at the 
same time. Starting by varying parameters until the optimal shapes and dimensions 
are achieved. More than 50 microfluidic channels were fabricated at the same time, 
each of them was reused in several experiments. The real microfluidic channel used 
in the experiments is depicted in figure 3.13. 
 
Figure 3.13. (Left): Microfluidic layout. (Right): The microfluidic system with 
the channel.  
With the aim of placing the PDMS microfluidic system on the photonic chip 
accurately aligned upon the sensing structures, a flip chip machine (Fine-tech) with 
a tolerance of alignment of only few microns was used to exactly positioning the 
PDMS on the photonic structures integrated on the SOI chip and align the 
microfluidic channels with the series of the sensing structures, as can be seen in 
Fig. 3.14. Once the microfluidic channel is aligned with the sensing structures, a 





Figure 3.14. Representation of the inverted flip chip microfluidic system 
positioning. 
Figure 3.15 depicts the experimental optofluidic setup used to monitor in real-time 
the response of the photonic sensing structures during the implementation of the 
biofunctionalization process. Once the SOI photonic chip is silanized to obtain a 
vinyl-terminated layer on its surface, it is assembled with the PDMS microfluidic 
flow cell ((400 µm × 50 µm × 6 mm (width × height × length)) channel size, which 
is accessed via 2 polytetrafluoroethylene (PTFE) tubes. The assembled photonic 
with the fluidic chip is placed on the sample holder of the experimental setup and 
fixed using a polymethyl methacrylate (PMMA) lid. PDMS and PMMA have been 
used for the realization of the flow cell and the lid respectively, as they are 
transparent to UV light and allow to irradiate the photonic chip during the 
characterization of the photocatalyzed biofunctionalization process.  
To characterize the photonic chip in our setup, light from a continuous sweep 
tunable laser is coupled to the input grating couplers using a fiber collimator. Light 
coming out from the output grating couplers is measured using an infrared (IR) 
camera synchronized with the tunable laser in order to obtain the spectra of all the 
PBG sensing structures within the chip simultaneously (Ruiz-Tórtola et al., 2018). 
The target solutions were flowed using a syringe pump in withdraw mode and set 
to a constant flow rate of 10 μL/min which was implemented after experimental 
optimizations, being notably lower than the calculated maximal flowrate to ensure 





Figure 3.15. (Top) Schematic representation of the measurement set-up. 
(Bottom right) Experimental setup employed for the interrogation of the 
photonic chip containing the PBG sensing structures. (Bottom left) Zoomed 
image that depicts the assembled opto-fluidic system with the chip. 
Once the opto-fluidic system was optimized, the next step is transferring the 
biofunctionalization assay from microarray format to an in-flow mode over the 
PBG sensing structures to monitor the light-assisted biofunctionalization process in 
real-time. Figure 3.16 shows the initial spectra in phosphate buffered saline (PBS) 
1× of the photonic sensing structures from one sensor group having their PBG 
located within the measurement range. It is noteworthy to comment that the PBG 
edge for the wi = 140 nm structure was not observed because it fell outside our 
measurement wavelength range. We can see that the increase of the width of the 
transversal elements wi produces a shift of the PBG edge towards longer 
wavelengths. Here, the position of the lobe appearing at the PBG edge will be 
tracked to monitor the spectral shift when the biofunctionalization events take place 




Figure 3.16. Initial spectrum in phosphate saline buffer (PBS) 1× for the PBG 
sensing structures within one sensors group (transmission units are given by the 
analog-to-digital converter (ADC) values provided by the IR camera). Note that 
the spectrum for the PBG sensing structure with wi = 140 nm is not depicted 
because its PBG edge is above the measurement wavelength range. 
 
3.7. Real-time monitoring of the hIgG immobilization 
Figure 3.17 shows the real-time monitoring results obtained for the UV light-
assisted immobilization of half-antibodies over the photonic chip. The sensing 
response from those PBG sensing structures having a width of the transversal 
elements of wi = 120 nm for the 4 sensor groups is depicted. Initially, PBS 1x is 
flowed over the vinyl-terminated photonic chip to obtain the initial baseline. Then, 
the solution containing the haBSA (20 µg/mL in PBS 1×) is flowed. As it can be 
observed in figure 3.18, no photonic sensing response is obtained at that moment 
for any of the PBG sensing structures despite both the vinyl groups of the SOI 
surface and the thiol moieties of the haBSA are present. It is not until the photonic 
chip is irradiated with UV light (at 254 nm with a power of 6 mW/cm2) and the 
vinyl-thiol reaction is photocatalyzed and hence the haBSA are immobilized upon 
the sensor surface, which is translated into a shift of the PBG position. Finally, PBS 
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1× buffer is flowed again to determine the net spectral shift and to remove any 
excess of the non-bounded haBSA. 
 
Figure 3.17. Temporal evolution of the PBG spectral shift during the real-time 
monitoring of the UV light-assisted immobilization of the thiol-terminated 
haBSA over the vinyl-terminated SOI surface. haBSA are injected at minute 8 
and the UV light source is switched on at minute 19. 
We can observe that the sensing response is different for each PBG sensing 
structure belonging to a different sensors group, being higher for those sensor 
groups placed in a central location of the chip (groups 2 and 3). This is related with 
the fact that a perfectly homogeneous illumination of the whole photonic chip 
surface has not been possible due to the presence of the PDMS flow cell, the PMMA 
lid, and the PTFE tubing on top of the photonic chip, as well as by the limited space 
to place the UV lamp in the experimental set-up (see figure 3.16). In this context, a 
better illumination of the central PBG sensors (groups 2 and 3) is produced, which 
is translated into a higher haBSA immobilization efficiency for those sensors, thus 
providing a higher spectral shift. 
It is also noteworthy to mention that after this biofunctionalization step, 1 µg/mL 
BSA in PBS 1x was flowed in order to obtain a certain detection. The results 
showed a very small PBG shift. From here, an optimization of the 




In this chapter, a UV light-assisted biofunctionalization protocol for the 
immobilization of thiol-terminated bioreceptors onto vinyl-terminated silicon-
based sensors was implemented. The fact that UV light is required to induce the 
immobilization allows to only biofunctionalize those specific positions where the 
sensing structures are placed, which offers a new way to obtaining higher density 
of nanoscale biosensing structures being biofunctionalized with different 
bioreceptors for a large-scale multiplexing level.  
Also, we have been able to monitor this photocatalytic immobilization in real-
time using an integrated nanophotonic sensing chip, showing that vinyl groups in 
the surface and thiol groups from the bioreceptors do not react until UV light is 
present. This result shows the feasibility of using nanophotonic sensors as a tool to 
study the mechanisms of photo-induced reactions in real-time. Additionally, this is, 
to our knowledge, the first time that photonic sensing structures are 
biofunctionalized with half antibodies, which can also mean an advantage in terms 
of higher surface coverage density, lower thickness of the recognition layer, and 
proper orientation of the antibodies binding sites and hence the enhancement of the 
sensitivity of the  photonic sensors.  
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BSA and CVD 
biomarkers detection 
by PBG biosensors  
4.1. Introduction 
In this chapter, we present the experimental work carried out to characterize and 
enhance the interaction with the target analytes in evanescence wave-based sensors, 
specifically for the case of PBG sensing structures, and thus to increase their 
sensitivity. After designing and fabricating the PBG sensing structures, its 
evanescent field has been thoroughly characterized using Scanning Near Field 
Optical Microscopy (SNOM) to determine how the interaction will vary with the 
distance to the sensor surface. Then, the PBG structure has been biofunctionalized 
to use it for biosensing purposes. Here, the biofunctionalization protocol was 
modified considering that the direct in-flow biofunctionalization presented in the 
previous chapter gave very low detection results. Therefore, the UV-induced 
immobilization of the half antibodies was carried out by spotting, what may 
enhance the surface concentration of the bioreceptor over the PBG sensors, since 
the UV lamp alignment, space and the tubing issues were avoided, which may lead 
to an enhancement of the detection signal. 
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PBG biosensing experiment has been first launched for Bovine Serum Albumin 
(BSA) detection previously to the CVD biomarkers detection assays with the aim 
of the system optimization. A global scheme of whole experiments is described in 
the next figure. 
 
Figure 4.1. Brief scheme of the whole protocol. 
Finally, CVD biomarkers such as CRP, Mb, cTnI and cTnT were detected at the 
required concentrations by modifying when needed, the recognition layer over the 
PBG sensing surface.   
 
4.2. Scanning Near Field Optical Microscope (SNOM) 
characterization 
Given the importance of the evanescent field profile over the sensing performance, 
the near-field behavior of the PBG sensing structures has been studied using SNOM 
technology, which has been used in previous works to characterize SOI structures 
as nanoatennas (Díaz-Fernández et al., 2018; Espinosa-Soria et al., 2018). SNOM 
measurements were performed with a tailored MultiView 4000 system (Nanonics 
Imaging Ltd.) working in collection mode as schematized below (see figure 4.2). A 
cleaved single mode optical fiber was used to couple light from a tunable laser 
(Keysight 81980A) to the photonic structures on the chip via their input grating 
couplers. A bent fiber tip with a 500 nm aperture, Cr/Au coated, pre-mounted on a 
tuning-fork working in tapping mode at 36.19 kHz was used to scan the photonic 
structures and measure the near-field signal using a FWPR-S Femtowatt 
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Photoreceiver. This tip was placed perpendicular to the sample, allowing a mode 
matching between the tip and the measured structures (Bazylewski et al., 2017; 
Dvořák et al., 2017). The whole system (photonic chip, input fiber and SNOM tip) 
can be previsualized with an optical microscope that enables a correct input fiber-
chip alignment and an accurate positioning of the SNOM probe on top of the PBG 
structure. 
 
Figure 4.2. Schematic view of the SNOM characterization set-up. 
Figure 4.3 shows the SNOM signal measured for one of the PBG sensing structures 
having the transversal elements of width wi = 120 nm for different excitation 
wavelengths and for an air upper cladding. Excitation wavelengths between 1530 
nm and 1580 nm have been considered in the measurements. SNOM images 
obtained for wavelengths 1530 nm and 1540 nm show a high back-scattering signal 
at the input of the PBG structure and no transmission was observed through the 
structures, thus confirming the presence of the PBG region. For wavelengths from 
1550 nm to 1580 nm, transmission over the whole PBG structure can be observed, 
thus indicating that the Bloch modes of the structure are being excited and that we 
are out from the PBG. Note that some backscattering is observed at the access of 
the PBG structure for all the excitation wavelengths except for 1570 nm, indicating 
that an optimal coupling is produced for this wavelength. Note that the PBG edge 
position determined for SNOM measurements is around 1550 nm, while the PWE 
and FDTD simulations predicted a PBG edge located around 1530 nm. This 
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difference can be attributed to slight variations in the dimensions of the fabricated 
structure or to the presence of SiO2 residues when opening the channel over the 
PBG sensing structures. 
 
Figure 4.3. SNOM measurements obtained at different wavelengths (from 1530 
nm to 1580 nm) for a PBG sensing structure having transversal element of width 
wi = 120 nm. The measurements are done at 20 nm from the PBG structure 
surface. 
Once the near field behavior of the PBG sensing structure was characterized 
depending on the operation wavelength (i.e., inside or outside the PBG), the next 
step was measuring the decay length of the evanescent field to characterize how the 
sensing interaction will vary with the height. Figure 4.4 (a) shows the SNOM 
measurements performed at different distances from the surface of the structure for 
an excitation wavelength of 1570 nm (which provided the best coupling to the PBG 
structure). These SNOM images show how the intensity of the evanescent field 
significantly decreases for heights above 100 nm.  
This SNOM characterization was performed in parallel to a simulation study in 
order to compare the evanescent wave behavior experimentally and 
computationally. To this aim, FDTD simulations were done using CST Microwave 
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Studio, which is specially created to solve electromagnetic problems in three 
dimensions where the working frequencies are high, as it is the case that concerns 
us. For our simulations, a 61 period PBG structure has been considered, such as for 
the one manufactured (Espinosa-Soria et al., 2018). To perform the system of 
equations that the simulation resolves, a hexahedral type mesh has been performed 
with 1.34 million cells, with at least 4 divisions per wavelength. The FDTD 
propagation simulations were carried out and the evanescent field intensity was 
measured for the same heights used in the SNOM measurements, as shown in figure 
4.4 (b). Note that as a shift of about ~20 nm of the PBG edge position was observed 
between the experimental characterization and the simulations, FDTD propagation 
results have been obtained using an excitation wavelength of 1550 nm to consider 
the same scenario than in the SNOM characterization. Both for the SNOM 
measurements shown in figure 4.4 (a) and for the FDTD simulations shown in 
figure 4.4 (b), maximum values of the evanescent field intensity over different 
periods of the PBG structure were obtained and represented in figure 4.4 (c) as a 
function height. As it can be observed in the graph, a strong exponential decrease 
of the evanescent field intensity is observed, thus confirming the need of performing 
the biodetection as close to the sensing surface as possible for a higher sensitivity. 
Note also the almost perfect agreement between the experimental SNOM 




Figure 4.4. (a) SNOM measured and (b) FDTD simulated near-field at different 
vertical distances (ZLIFT) from the surface of the PBG sensing structure. An 
excitation wavelength of 1570 nm is used for the SNOM measurements, while a 
wavelength of 1550 nm has been used in the FDTD simulations. (c) Normalized 
intensity of the evanescent field as a function of the distance to the sensor 
surface for the SNOM measurements (purple color) and for the FDTD 
simulations (blue color). The shaded areas represent the standard deviation of 
the raw SNOM measurements and the FDTD simulations along the area of the 
PBG structure highlighted in the insets. 
Since SNOM setup does not allow to perform near-field measurements of the 
photonic structures when having a water upper cladding and considering the good 
agreement between simulations and experiments previously shown, we have used 
FDTD simulations to determine the evanescent field profile in that scenario. Figure 
4.5 shows the electric field profile simulated when considering air and water upper 
cladding, as well as the variation of its intensity as a function of the distance to the 
sensor surface for these two scenarios. Note that, to consider an equivalent situation, 
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both simulations have been made considering an excitation wavelength located at 
~20 nm from the selected PBG edge (i.e., 1550 nm for an air upper cladding and 
1600 nm for a water upper cladding). As it can be observed, the decay profile of the 
evanescent field in air and in water are in match. 
 
Figure 4.5. (a, b) FDTD simulated electric near-field intensity (V/m) through 
the PBG structure for air (λ = 1550 nm) and water upper cladding (λ = 1600 
nm), respectively. (c) Variation of the electric field intensity as a function of the 
distance to the sensor surface for the FDTD simulations when considering an air 
(blue color) and a water upper cladding (red color). The shaded areas represent 
the standard deviation of the intensity along the PBG structure. 
 
4.3. Drop-casting half antibody biofunctionalization 
As determined from the evanescent field characterization by means of SNOM 
measurements and FDTD simulations, a very thin biorecognition layer is required 
for an optimum interaction of the biosensor with the target analytes. In order to 
achieve that thin biorecognition layer, we have developed the light-assisted 
biofunctionalization approach that allows the covalent immobilization of thiol-
terminated bioreceptors onto a vinyl-terminated surface as explained in the previous 
chapter. But in this case, since the in-flow biofunctionalization strategy previously 
used in chapter 3 gave very low detection signal in the following biosensing assay, 
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now we have immobilized the hIgG by spotting it over the sensing structures as 
depicted in figure 4.6. Here, 2 µL of 20 µg/mL rabbit half BSA antibodies have 
been drop casted over the sensing area and irradiated for 5s using the UV lamp (254 
nm with 50 mW/cm2). Considering the thickness of the initial organosilane layer 
(~4.5 nm) as obtained from ellipsometry measurements, and by estimating the 
thickness of the half antibodies deposited on the surface (~2.5 nm), we determine 
that a total thickness of the whole biorecognition layer of only ~7 nm was achieved. 
When determining the immobilization density by fluorescence microarray format, 
densities corresponding to a close-packed monolayer of the half antibodies were 
obtained with standard deviation of 8% indicating a good reproducibility in the 
immobilization method. 
 
Figure 4.6. (a) haBSA cleavage protocol. (b) Light-assisted immobilization of 
the thiol-terminated haBSA onto the vinyl-terminated surface of the PBG 
sensing structures by spotting. 
 
4.4. Direct and real-time BSA detection 
For the BSA real-time detection, the employed measurement set-up and the tracking 
process is identical to that previously described in chapter 3.  
Before performing the BSA detection experiment, a bulk sensitivity test was carried 
out. The sensitivity experiment consists basically on the flow of pure Deionized 
Water (DIW) followed by a mixture of DIW and 5% of ethanol (EtOH) and back 
to pure DIW. This experiment is performed to determine the bulk sensitivity of our 
different wi sensing structures to changes of the refractive index (RI) of the 









Figure 4.7. Sensitivity test carried out for different wi sensing structures. 
As previously described in (García-Rupérez et al., 2010), the refractive index of 
DIW and EtOH dilutions for ethanol proportions below 6% in volume is linearly 
approximated as: 
n dilution = 1.024 x (%/100) x n EtOH + 1 x (1-%/100) x n DIW. Equation 4.1 
From here, we determine that the RI of the DIW-EtOH dilutions for our working 
conditions (λ≈1550 nm and T≈25°C) are nDIW = 1.3173 and nDIW-EtOH 5% = 1.3199. 
The sensitivity equation is represented as following: 





where S is the sensitivity, Δλ is the measured wavelength shift and Δn is the 
refractive index variation. By using the measured wavelength shifts from figure 4.8 
and considering the refractive index variations calculated from equation 4.1, we 
determine the sensitivities of our sensors as shown in table 4.1. 
Table 4.1. Experimental sensitivities of wi=80, 100 and 120 nm PBG structures in (nm/RIU). 
 wi=80 nm wi=100 nm wi=120 nm 
Sensitivity (nm/RIU) 165.38 215.38 292.3 
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We can observe that a higher sensitivity is obtained when wi increases, thus 
indicating a better interaction of the light with the upper cladding medium. 
A blank test was performed to check the detection system availability. First, 
fluorophore-labelled detection antibody was deposited directly over the SOI surface 
biofunctionalized with BSA half antibodies without the presence of the target BSA 
antigen in between, and then it was rinsed with the buffer again to eliminate the 
BSA antibody excess. No fluorescence was detected, what confirms that the 
specificity test was successful. 
Once the sensitivity and selectivity studies were successful, a direct detection BSA 
experiment was performed. Figure 4.8 shows the results obtained for one of the 
groups of PBG sensing structures in the biosensing experiments carried out. After 
an initial flow of PBS-T buffer (PBS + 0.01% Tween 20) for 10 minutes to establish 
the baseline, BSA at 1 µg/mL in PBS-T was flowed over the biofunctionalized PBG 
sensing structures for 20 minutes for the real-time detection of the target antigens. 
Then, PBS-T buffer was flowed again for 10 minutes to eliminate BSA excess. Note 
that PBS-T buffer was employed in these experiments to prevent non-specific 
interactions and BSA adsorption. As it can be observed in figure 4.9, the target BSA 
was successfully detected by the PBG sensing structures, obtaining shifts of 50, 95 
and 140 pm for structures having wi = 80, 100 and 120 nm, respectively. Note that 
results for the PBG structure having wi = 140 nm have not been included because 
its PBG edge was out from our measurement range. From the experimental results 
of the figure 4.7 and figure 4.8, we can also observe the great influence of the wi 
parameter of the PBG structures over their sensitivities, obtaining an increase of the 
shift of 45 pm every time that the width parameter wi is increased by 20 nm in the 
BSA detection experiments. Finally, fluorophore labelled antiBSA at 20 µg/mL was 
flowed with the aim of the verification of the surface homogeneity by checking the 
fluorescence intensity. Figure 4.9 shows the high homogeneity and intensity over 
the whole sensing area confirming the adequate realization of all the steps of 




Figure 4.8. Experimental results of the real-time direct detection of BSA. 
Experimental data corresponding to the different wi PBG structures. 
 
Figure 4.9. Fluorescence intensity test of the photonic chip. (inset) chip image 
after the flow of the fluorophore-labelled antiBSA. 
Once we performed the direct real-time detection of the BSA successfully, the 
following step is the application of this strategy for the previously mentioned CVD 
biomarkers detection.  
4.5. Direct and real-time detection of CVD biomarkers 
Previously to the CVD detection performance, we performed a selectivity study in 
order to confirm the selectivity of the half antibodies. First, CRP half antibodies 
were drop casted and UV light irradiated to biofunctionalize a flat SOI surface; then 
fluorophore-labelled BSA was incubated for 30 min and the fluorescence was 
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checked after cleaning by PBST, obtaining no fluorescence signal. No PBG shift 
was detected, and the fluorescence test gave no fluorescence, so the results confirm 
the selectivity of the half antibodies.  
Once the selectivity was checked and the biofunctionalization protocol was 
optimized and the detection of BSA was correctly achieved, the next step of CVD 
biomarkers detection will consist on the biofunctionalization of the sensing surface 
by means of drop-casting of the specific half antibody of each antigen. Note that 
for very low CVD biomarkers concentrations cases, a fluorophore-labelled 
detection antibody is flowed in the end in order to enhance the detection signal (the 
PBG shift). 
 
4.5.1. C-Reactive Protein (CRP) detection 
Here, we apply our photonic sensing system based on PBG sensing structures 
previously described and applied for BSA to detect the CRP. Here, the chemical 
surface functionalization was carried out using the TEVS 1% in water carrier and 
the biofunctionalization protocol carried out was by drop casting the half antibody 
of CRP (haCRP). Here, the protein concentration to detect is of 250 ng/mL. The 
other conditions were the same as applied for BSA detection experiment. Results 
are depicted in figure 4.10. 
 
Figure 4.10. 250 ng/mL CRP direct detection and representative scheme. 
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The obtained detection results are for the PBG structure with wi=120 nm. In the 
biosensing experiments carried out, after an initial flow of PBS-T buffer (PBS + 
0.01% Tween 20) for 20 minutes to establish the baseline (5 minutes might be 
enough as well), 250 ng/mL of CRP in PBS-T was flowed over the 
biofunctionalized PBG sensing structures for 15 minutes for the real-time detection 
of the target antigens. Then, PBS-T buffer was flowed again to eliminate CRP 
excess. As it can be observed in figure 4.10, the target CRP was successfully 
detected by the PBG sensing structure, obtaining a shift of 65 pm, in the same order 
as found by ring resonators for 100 ng/mL (Luchansky et al., 2011).  
After the CRP detection, a more specific biomarker for CVD is a must, since as 
previously mentioned in chapter 1, CRP is an inflammation marker and predicts 
cardiovascular diseases only in healthy non-inflammatory patients. From here, we 
will attempt the detection of other specific biomarkers for CVD. 
 
4.5.2. Myoglobin (Mb) detection 
In our real-time biophotonic detection of Mb, a concentration of 20 ng/mL has been 
flowed. In this time, real human serum (10%) was used with the PBS-T buffer as a 
carrier to prevent the conformational changes of the protein, and hence preserve its 
stability. Also, the introduction of a real matrix such as human serum is a good 
milestone to checkup the availability of our sensing system in presence of non-
targeted elements (e.g., lipids, cells, proteins…). Note that control tests for human 
real serum were done previously in microarray configuration with no interferences 
to the bioreceptors. Finally, specific myoglobin antibody was flowed for signal 




Figure 4.11. 20 ng/mL Myoglobin detection and representative scheme. 
First, buffer composed by PBST+ human serum 10% was flowed during 10 minutes 
in order to establish the baseline. Then, 20 ng/mL of Mb in the same buffer was 
flowed for 15 min. Afterwards, buffer was flowed again for 15 minutes to eliminate 
a possible Mb excess before flowing a fluorophore-labelled detection antibody in 
the same buffer for 15 minutes as well. Finally, 10 minutes of buffer was flowed 
for the fluorophore-labelled Mb detection antibody excess elimination. A 
fluorescence test was successfully carried out to double check the detection 
intensity and homogeneity. 
Myoglobin direct detection gave a PBG shift of about 20 pm. This shift is smaller 
comparing to CRP, because from a side, the size and shape of Mb are considerably 
smaller than CRP, and from the other side, the concentration flowed is significantly 
lower (<0.1x) than for CRP. From here, the need of the Mb detection antibody flow 
with the aim of enhancing and amplify the sensing signal. Since its size and shape 
are bigger, Mb detection antibody provokes a shift of 70 pm, thus enhancing the 






4.5.3. cTnI and cTnT detection 
As previously introduced in chapter 1, clinical studies backed up by bibliographical 
works (Collinson et al., 2001; Ridker, 1999; Sagarad et al., 2012) have shown that 
cTnI levels > 10 ng/L is a CVD high risk biomarker level, being 1 ng/L a normal 
cTnI level in bloodstream. Within the PHOCNOSIS project, besides the working 
on the photonic biodetection, several partners are involved in other aspects, like the 
electronics, integration and micro/-nanofluidics. The last one has a special interest, 
since it targets the development, fabrication and testing of a microfluidic cell which 
is able to concentrate and filter the real human sample. Briefly, it consists in a 
PDMS cell with several chambers to fill with the buffers and the target sample. By 
applying an electrical field, the components of the sample are separated by charge 
allowing the increase of the concentration of sample components in different 
locations of the microfluidic channel. With this achievement, a protein 
concentration may increase about x1000. From here, the cTnI and/or cTnT 
concentrations we should detect using the photonic sensors are in the level of 1 
ng/mL and 10 ng/mL, respectively, which is the range of our photonic biosensing 
assays. 
As previously done in the rest of biosensing experiments, we apply the same 
chemical and biochemical functionalization scheme except that the half antibody 
immobilized on the surface is now specific for cTnI. 100 ng/mL of cTnI were 
flowed over the PBG biosensing surface. Note that cTnI is again flowed using a 
buffer composed by 10% real human serum in PBST as for Mb biodetection case, 
to prevent the conformational changes and structural damage of the cTnI protein. 




Figure 4.12. 100 ng/mL cTnI detection and representative scheme. 
Here, we start flowing PBST + human serum 10% during 10 minutes in order to 
establish the baseline. Then, 100 ng/mL of cTnI in the same buffer was flowed for 
30 min. Afterwards, the buffer with human serum was flowed again for 20 minutes 
to eliminate cTnI excess before flowing a fluorophore-labelled detection antibody 
in the same buffer for 20 minutes as well. Finally, 10 minutes of the buffer was 
flowed for the cTnI detection antibody excess elimination. A fluorescence test was 
carried out successfully to double check the achieved detection. 
100 ng/mL of cTnI direct detection gave a resonance shift of about 50 pm. This 
shift is higher compared to that obtained for Mb, because the size, shape and the 
concentration of cTnI are also higher than Mb. To keep the same strategy, cTnI 
detection antibody is flowed with the aim of enhancing and amplifying the sensing 
signal. Since its size is higher, anticTnI triggers a shift of 25 pm, providing a total 
detection shift for cTnI 100 ng/mL of 75 pm. Here, the issue is that the fluorophore-
labelled cTnI detection antibody should have provoked a higher PBG shift than the 
cTnI protein itself (see figure 4.11). 
For the next experiment we shift to another CVD biomarker which is the cTnT. 
Here, 10 ng/mL of cTnT protein detection assay was performed following the same 
protocol as the previous experiment. As it can be observed in figure 4.13, no shift 
was observed for the direct detection of 10 ng/mL of cTnT, mainly determined by 
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the low concentration of the target. However, a shift of around 35 pm was observed 
when the secondary antibody was flowed. 
 
Figure 4.13. 10 ng/mL cTnT detection and representative scheme. 
We also tried to detect a lower concentration of cTnT (1ng/mL), but it was 
unsuccessful. Therefore, in order to deal with this issue, we tried another 
biofunctionalization protocol that may overcome these limitations and enables us 
to achieve the required detection limit of 1 ng/mL.  
 
4.6. Protein G based biofunctionalization for 1 ng/mL cTnT 
detection 
We have tested an alternative biofunctionalization approach in order to assess if it 
was possible to reduce the detection limit of our biosensing experiments. Here, we 
perform another kind of biofunctionalization consisting on direct physical 
adsorption. Briefly, this methodology is based on the adsorption of a protein 
(mostly protein A and/or G) followed by the biofunctionalization with the whole 
antibody and the blocking of the non-bounded sites of the adsorbed protein before 
the biodetection assay (Caroselli et al., 2018). The approach presented here might 
be an efficient alternative to the previously used techniques, as it allows to 
overcome their drawbacks because it enables the presence of double epitopes 
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number than for half antibody. Moreover, the proper antibody orientation provided 
by the presence of the protein A or G layers is translated into a better sensitivity of 
the photonic structure. Additionally, the whole biofunctionalization process can be 
directly applied in-flow, thus allowing to flow all the reagents of the whole 
experiment (from the biofunctionalization to the detection) avoiding dispersed 
functionalization steps with their respective error margins. 
Within this context, the PBG sensing structures biofunctionalization is based on the 
physical adsorption immobilization of the protein G as an intermediate layer to 
immobilize the antibodies. So, the antibodies can be anchored to the sensing surface 
by binding to protein G, which is a microbial surface protein derived from 
streptococcus cell. Protein G contains four binding sites specific to the common Fc 
region of the antibodies. Thus, it specifically binds with Fc regions of the antibodies 
while the Fab regions stays available, exposed and neatly oriented towards the 
sample solution including the target protein to be detected. Furthermore, the 
regeneration is easier in contrast to covalently linked antibody to the surface, since 
it is possible to break this binding by using the chaotropic agents (glycine, NaOH, 
NaCl, …) in order to biofunctionalize again with a new batch of antibodies of the 
same kind and repeat the same experiment or either the use of another type of 
antibodies and carry out a different sensing assay. The complete protocol is 
schematized in figure 4.14. 
 
Figure 4.14. (A) Schematic representation of the biofunctionalization protocol 
and (B) schematic representation of the detection.  
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First, we start flowing protein G over the PBG sensing structures with the aim of 
the creation of the protein G intermediate layer by physical adsorption, which will 
ensure us a high surface coverage and oriented immobilization of the antibody. 
First, PBS was flowed during 10 minutes in order to stablish a baseline. Then, 
protein G in PBS with a concentration of 20 µg/mL at 10 µL/min flow rate was 
flowed during 20 minutes before we flowed again the PBS to eliminate the excess 
of protein G. Note that we do not use PBST in this case, since the surfactant does 
not help promote the physical surface adsorption. Here, 100 pm of PBG shift was 
observed due to the physical adsorption of the protein G over the sensing surface. 
Results are presented in figure 4.15. 
 
Figure 4.15. Protein G adsorption over the sensing surface and representative 
scheme. 
After the creation of the intermediate layer of protein G, cTnT antibody was flowed 
at a concentration of 20 µg/ml in PBST over the sensing surface with the adsorbed 
protein G layer. Here, the tween 20 surfactant is used to avoid the adsorption of the 
cTnT antibody on the sensor surface, since that physical adsorption of the antibody 
might provide non-oriented antibodies, thus decreasing the sensing capability. 
Furthermore, the interaction of the antibody with the protein G is a binding 
interaction between the Fc region of the cTnT antibody and the protein G binding 
sites. PBST buffer was flowed for 10 minutes to settle a baseline before flowing 20 
µg/mL of rabbit anticTnT for 25 minutes to bind the antibodies to the Fc protein G 
binding sites. Then, PBST is flowed once again for 10 minutes to eliminate the 
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excess of the anticTnT. A total shift of 120 pm was achieved, as depicted in figure 
4.16. 
 
Figure 4.16. anticTnT binding to the protein G and representative scheme. 
The next step consists on the blocking antibody flow. It is used with the aim of 
blocking the available non-bounded sites of the protein G by anticTnT. A higher 
concentration (200 µg/mL) was flowed to ensure the complete blocking of the 
available protein G sites. Here, a PBST buffer baseline was stablished for 13 
minutes before the flow of the blocking antibody in the same buffer for 15 minutes. 
Then, the buffer was flowed again to eliminate the antibody excess, from here the 
signal decrease starting from min 28. The total net shift was in the order of 280 pm. 
Results are depicted in figure 4.17. 
 
Figure 4.17. Blocking antibody binding to protein G and representative scheme. 
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Once the biofunctionalization process was completed, we proceeded with the 
detection of 1 ng/mL of cTnT. As previously performed for other CVD biomarkers, 
the detection protocol will be based on the flow of the PBST buffer with real human 
serum at 10% for 10 min followed by the flow of the target protein cTnT for 15 
min. The buffer is flowed again in order to eliminate excess of cTnT and finally 
anticTnT is flowed for 20 min in order to amplify the sensing signal. Finally, the 
buffer was flowed to eliminate the rests of the fluorophore-labelled detection 
anticTnT antibody. Results are depicted in the figure 4.18. 
 
Figure 4.18. 1 ng/mL cTnT protein detection and representative scheme. 
Here, and when 1 ng/mL of cTnT achieves the sensing structures, we can observe 
a slight shift of about 10 pm which is enhanced by 100 pm when the detection 
antibody is flowed, making the total PBG shift reaching 110 pm.  
 
4.7. Conclusions 
In this chapter, we have developed a photonic biosensing system based on PBG 
sensing structures for the specific detection of proteins. First, we have performed a 
study of the evanescent field profile. A strong exponential decay has been observed 
in the SNOM characterization carried out, thus highlighting the importance of 
having a biorecognition layer as thin as possible for a high sensitivity detection. 
Additionally, note that a good agreement has been observed between SNOM 
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experimental measurements and FDTD near field behavior simulations, thus 
making this simulation method appropriate for characterizing evanescent field 
photonic sensors with a high accuracy. 
To fulfill the requirement of having a very thin biorecognition layer, we 
implemented the TEC biofunctionalization protocol. Then, and by means of BSA 
detection experiments, we have confirmed that a high sensitivity is obtained. We 
have also observed that this sensitivity might also be higher by properly tuning the 
structural dimensions of the PBG sensing structures, as simply an increase of the 
transversal elements width was translated into a sensitivity increase by approx. ×3. 
Next, CVD biomarkers such as CRP and Mb were detected. The CRP was detected 
directly at 250 ng/mL with a net PBG shift of 65 pm whereas the Mb was detected 
with 20 pm directly and up to 90 pm by flowing the detection antibody. Then, cTnI 
at 100 ng/mL gave a 50 pm PBG shift while a direct detection when the detection 
antibody increases this detection until 75 pm. The decrease of the concentration to 
10 ng/mL with a shift to cTnT was performed for the next experiment. Here, 10 
ng/mL of cTnT only gave PBG shift due to the flow of the detection antibody with 
a PBG shift of 35 pm. For 1 ng/mL of cTnT, no PBG shift was observed. So, we 
have to deal with the issue by changing the functionalization protocol. This 
biofunctionalization way was based on the protein G physical adsorption upon the 
sensing surface and antibody functionalization was used with successful results 
regarding the decrease of the experimental limit of detection, which demonstrates 
among others, the functionalization versatility of the PBG sensing structures. In our 
knowledge, this is the first time that 1 ng/mL of a cTnT biomarker is detected using 
a PBG biosensor. Moreover, direct detection of lower normal range concentration 
of CRP (250 ng/mL) was directly detected without need of the detection antibody. 
These results are highly important, since they may open a wide range of applications 
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Conclusions and future 
steps 
5.1. Conclusions 
In this PhD Thesis, we have started studying theoretically and computationally the 
binding of the cardiac troponin I CVD biomarker with its antibody. First, it was 
necessary to determine the binding sites of the antibody and the antigen as well. 
This step was performed using FTSite and FTMap with the aim of determining 
these binding regions or hot spots. Then, a computational docking was made using 
pyDock and FTDock to determine the availability, strength of the binding and 
number of bonds between the cTnI and the anticTnI. This work was complemented 
by a computational selectivity study by introducing the skeletal troponin I (sTnI) as 
principal interferent. The obtained results show the higher specificity of the 
anticTnI to the cTnI rather than sTnI. 
Next, a real-time biofunctionalization study was performed over the PBG sensing 
structures, which were nanofabricated on a chip including 16 structures varying the 
parameter wi (80, 100, 120 and 140 nm) allowing to have PBGs in different 
wavelengths. This chip was integrated in an optofluidic set-up to track in real-time 
the PBG shift during the UV-light assisted biofunctionalization process. On the 
other side, BSA antibodies were divided using the TCEP protocol in order to obtain 
two SH-terminated moieties. This part was done in collaboration with UPV-SYM. 
The chip was silanized using TEVS and integrated with the microfluidic cell and 
aligned in the photonic set-up. Since the reaction of thiol-ene coupling is UV-light 
dependent, a 254 nm wavelength lamp was switched to photo-catalyze the TEC 
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reaction. The PBG edges were shifted towards different wavelengths due to the 
different sensitivities announcing the accomplishment of the half antibodies 
biofunctionalization to the PBG sensors. 
Also, Scanning Near-field Optical Microscope characterization was employed to 
experimentally study the evanescent field behavior. This study allowed us to better 
understand the evanescent field behavior and substantiate the availability of our 
biofunctionalization protocol to perform the sensing study with the optimal 
sensitivity. In fact, as thinnest is the biolayer, the interaction between the target 
analyte and the evanescent field is maximal and hence, the shift is higher for very 
low concentrations of the target analyte. 
Then, biodetection experiments were carried out, but changing the immobilization 
of the antibodies from an in-flow format to spotting in order to improve the surface 
coverage, volumes and time. The first experiments were carried out using the model 
system BSA-antiBSA at 1 µg/mL with successful detection results. Then, we tried 
with different CVD biomarkers systems some of them at clinical levels (CRP and 
Mb) achieving successful results. 
In order to further reduce the detection limit of our photonic biosensor, another 
biofunctionalization system was used and tested for cTnT detection. It consists on 
a physical adsorption of protein G, followed by binding of the antibodies at their Fc 
regions to the protein G layer, followed by the blocking of the non-bounded protein 
G sites using a blocking antibody. 1 ng/mL of cTnT detection was achieved 
satisfying the work objective. Here, the detection was done by means of the flow of 
the complementary antibody for the cardiac Troponin T. 
As general conclusion, we can say that the targeted detections were achieved, but 
several issues were observed. This may be due to the following reasons: 
 The nanofabrication gave some dimensions mismatches in wi (2 to 12 nm) 
and hence the PBG edges of the same parameters were localized in different 
wavelengths, thus varying the sensitivity. This issue was found in same 
structures at the chip and in different ones as well. 
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 The chemical functionalization was reproducible but not at 100%. For 
example, the Water Contact Angle (WCA) varies between 72º and 85º, what 
might be due to differences of the TEVS batches, volumes, temperature 
variations and/or humidity. 
 The half antibodies also show sometimes a low binding capability, what 
might indicate that there are also some variations in the TCEP reduction 
protocol used to obtain the hIgGs and either in their storage process. 
 The microfluidic system also presents some limitations, since sometimes 
bubbles, obstructions, changes in the flow rate and holder chip movements 
when changing the tubes in the experiments were observed in the signals, 
what influences the performance of the biosensing experiments. 
 
5.2. Future steps 
From the obtained results, many optimizations can be performed to overcome all 
the limitations found at this stage. For example, the use of other kind of receptors 
such as nanobodies, gold nanoparticles intermediates or either different photonic 
structures being easier to fabricate in our cleanroom facilities techniques in order 
to have more reproducible spectra and sensitivities and jump to the multiplexed 
detection milestone. However, the developed PBG sensing structures are hopefully 
available for micrograms per milliliter concentrations proteins detection. Also, as a 
semi-quantitative sensing system immunoassay tests, which can have several 
applications in a wide range of fields such as food industry, defense and other 
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